{
  "title": "M21-1, Part V, Subpart iii, Chapter 6 - Digestive Disabilities",
  "url": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014523/M21-1-Part-V-Subpart-iii-Chapter-6-Digestive-Disabilities",
  "content": "<-- Previous Section\nNext Section -->\nOverview\nIn This Chapter\nThis chapter contains the following topics:\nTopic\nTopic Name\n1\nAssigning Evaluations for Digestive Disabilities\n2\nService Connection (SC) Considerations Involving Digestive Disabilities\n3\nSC and Evaluation Considerations Involving Hepatitis\n1\n.\nAssigning Evaluations for Digestive Disabilities\nIntroduction\nThis topic contains information about assigning evaluations for digestive disabilities, including\nregulatory framework for assigning evaluations for digestive disabilities\nprohibition of separate evaluations for certain coexisting digestive disabilities\nevaluating coexisting digestive disabilities that cannot be separately evaluated\nexample of evaluating coexisting digestive disabilities\n, and\nchanges to the rating schedule for the digestive system\n.\nChange Date\nMay 20, 2024\nV.iii.6.1.a\n.\nRegulatory Framework for Assigning Evaluations for Digestive Disabilities\nDisabilities of the digestive system are rated using\n38 CFR 4.112\n(weight loss and nutrition)\n38 CFR 4.113\n(coexisting abdominal conditions), and\n38 CFR 4.114\n(the schedule of ratings for the digestive system).\n38 CFR 4.112\ndefines terms used in diagnostic criteria in\n38 CFR 4.114\nthat involve weight and nutrition.\n38 CFR 4.113\nprovides a general warning that certain coexisting digestive conditions (those listed in the prefatory instruction in\n38 CFR 4.114\n) cannot be separately evaluated without pyramiding.\n38 CFR 4.114\ncontains diagnostic codes (DCs) and associated criteria for disabilities of the digestive system.  It also contains a general principle that certain listed DCs cannot be separately evaluated and combined.\nV.iii.6.1.b\n.\nProhibition of Separate Evaluations for Certain Coexisting Digestive Disabilities\n38 CFR 4.114\nprohibits assigning separate evaluations for certain coexisting digestive disabilities.  The purpose of the prohibition, as is further explained in\n38 CFR 4.113\nand\n38 CFR 4.14\n, is so that digestive disabilities, particularly within the abdomen, with closely related overlapping manifestations will not be combined under\n38 CFR 4.25\n, resulting in extra compensation for the same disability or facet of disability.\nAssignment of separate evaluations for any combination of the following DCs is prohibited:\n7301 through 7329\n7331\n7342\n7345 through 7350\n7352, and\n7355 through 7357.\nExceptions\n:  Effective May 19, 2024,\n38 CFR 4.114\ndoes not categorically prohibit evaluating hiatal hernia separately from another condition in the above list, as long as the specific evaluations do not pyramid under\n38 CFR 4.14\n.  This is because as of that date, hiatal hernia (\n38 CFR 4.114, DC 7346\n) is evaluated using the diagnostic criteria for esophageal stricture (\n38 CFR 4.114, DC 7203\n), which is not included in the listed DCs.\nAdditionally, some DCs provide instructions to rate residuals\nnot addressed in the diagnostic criteria\nunder another DC.\n38 CFR 4.114, DC 7319\n(irritable bowel syndrome (IBS)) contains a note that says, “Evaluate other symptoms of a functional digestive disorder, not encompassed by this diagnostic code, under the appropriate diagnostic code, to include gastrointestinal dysmotility syndrome (DC 7356), following the general principles of § 4.14 and this section.”\nWhen the primary DC for the diagnosis, and a DC for rating other residuals not encompassed in the primary DC are both listed in\n38 CFR 4.114\n, the evaluations\ncan\nbe combined on a case-by-case basis as long as the symptoms used to provide each evaluation do not pyramid under\n38 CFR 4.14\n.\nImportant\n:\nWhere disabilities that fall within the range of DCs above cannot be separately evaluated and included in a combined evaluation, a single evaluation will be assigned as provided in\nM21-1, Part V, Subpart iii, 6.1.c\n.  As explained in that block, elevation of the evaluation may be appropriate.\nWhen separately evaluating and combining DCs is prohibited under\n38 CFR 4.114\n, the\nCodesheet\nmust still reflect each service-connected (SC) disability.\nNotes\n:\nSeparately evaluating and combining 7200-series DCs (such as Barrett’s esophagus) with a 7300-series DC (such as IBS or Crohn’s disease) is not categorically prohibited by\n38 CFR 4.114\n.\nSimilarly, separately evaluating and combining multiple 7200-series DCs is not categorically prohibited.\nWhenever considering DCs that are not included in the\n38 CFR 4.114\nlist above, always carefully consider whether specific diagnostic criteria will compensate the same facet of disability and therefore violate\n38 CFR 4.14\n.\nV.iii.6.1.c\n.\nEvaluating Coexisting Digestive Disabilities That Cannot Be Separately Evaluated\nUnder\n38 CFR 4.113\nand\n38 CFR 4.114\nwhen there are coexisting digestive disabilities for which multiple evaluations cannot be assigned\na single rating will be assigned under the DC which reflects the predominant disability, and\nthat evaluation will be elevated to the next higher evaluation when the severity of the overall disability warrants it.\nThe Veterans Benefits Management System – Rating (VBMS-R) Evaluation Builder is programmed to appropriately apply the provisions of\n38 CFR 4.114\nbut\nit is critical that\nthe user input the symptoms that support the elevation, and\nthe symptoms coincide with the criteria listed in the rating schedule.\nFor instructions on proper application of the\n38 CFR 4.114\nprovision on assigning an evaluation in cases of multiple qualifying coexisting digestive disabilities see the table below.\nStep\nAction\n1\nDetermine which of the coexisting digestive conditions is the predominant disability.\nImportant\n:\nTo determine the predominant disability, determine the evaluation each condition would support on its own.  The condition that has the highest disability evaluation is the predominant disability.\nIf the same evaluation would be assigned to each, go through the analysis in the steps, alternatively treating each condition as the predominant one to see if one alternative provides a more advantageous outcome to the Veteran.\n2\nDetermine if there are symptoms of the non-predominant disability that do not overlap with those of the predominant disability.\nIf\nyes\n, go to Step 3.\nIf\nno\n, go to Step 4.\n3\nReevaluate the predominant disability but this time also consider the non-overlapping symptoms of the non-predominant disability.\nImportant\n:  The non-overlapping symptoms must support a higher evaluation when applied to the DC criteria being utilized for the predominant disability.\nDetermine if the resultant evaluation is higher than the evaluation for the symptoms of the predominant disability alone (as derived in Step 1).\nIf\nyes\n, go to Step 5.\nIf\nno\n, go to Step 4.\n4\nRate the coexistent disabilities together under the rating criteria for the predominant disability\nwithout elevation\nto the next higher evaluation.\nNo further action necessary.\n5\nRate the coexistent disabilities together under the rating criteria for the predominant disability and elevate to the next higher evaluation.\nNo further action necessary.\nImportant\n:  The “next higher level of evaluation” is the lowest evaluation specified in the DC for the predominant disability\nthat provides greater compensation than the evaluation derived in Step 1\n(the evaluation that would be supported by only the symptoms of the predominant disability without the symptoms of the lesser disability).\nDo not simply add 10 percent\n.\nV.iii.6.1.d\n.\nExample:  Evaluating Coexisting Digestive Disabilities\nSituation\n:  A Veteran has two coexisting digestive disabilities:\npeptic ulcer disease meeting the criteria for a 20-percent evaluation under\n38 CFR 4.114, DC 7304\n(two episodes of abdominal pain lasting for three consecutive days in duration in the past 12 months managed by daily prescribed medication), and\nulcerative colitis of the large bowel, meeting the criteria for a 30-percent evaluation under\n38 CFR 4.114, DC 7323\n, which is evaluated using the criteria for Crohn’s disease or undifferentiated inflammatory bowel disease in\n38 CFR 3.114, DC 7326\n(mild disease managed with oral and topical agents other than immunosuppressants or other biologic agents, and characterized by recurrent abdominal pain with 3 or fewer daily episodes of diarrhea and minimal signs of toxicity including infrequent low grade fever).\nResult\n:\nSeparate\nevaluations for the peptic ulcer disease and ulcerative colitis are\nnot\npermitted under\n38 CFR 4.114\n.  A single 30-percent evaluation under\n38 CFR 4.114, DC 7323\nwould be assigned.\nExplanation\n:  Ulcerative colitis represents the predominant disability picture as it supports the higher evaluation on its own.\nThere are no non-overlapping symptoms of peptic ulcer disease to establish any of the criteria supporting the next higher 60-percent evaluation for ulcerative colitis:  moderate inflammatory bowel disease that is managed on an outpatient basis with immunosuppressants or other biologic agents; and is characterized by recurrent abdominal pain, four to five daily episodes of diarrhea; and intermittent signs of toxicity such as fever, tachycardia, or anemia.  Therefore, the coexistent disabilities must be rated together under the rating criteria for the predominant disability\nwithout elevation\nto the next higher 60-percent evaluation.\nSituation\n:  A Veteran has two coexisting digestive conditions:\nIBS, meeting the criteria for a 10-percent evaluation under\n38 CFR 4.114, DC 7319\n(abdominal pain related to defecation at least once during the previous three months; and two or more of the following: (1) change in stool frequency, (2) change in stool form, (3) altered stool passage (straining and/or urgency), (4) mucorrhea, (5) abdominal bloating, or (6) subjective distension), and\nhiatal hernia, meeting the criteria for a 10-percent evaluation under\n38 CFR 4.114, DC 7346\n, which is rated as stricture of the esophagus under\n38 CFR 4.114, DC 7203\n(documented history of esophageal stricture(s) that requires daily medications to control dysphagia otherwise asymptomatic).\nResult\n:  Effective May 19, 2024,\nseparate\nevaluations for IBS and hiatal hernia are permitted under\n38 CFR 4.114\n.\nExplanation\n:  Even though the DCs for hiatal hernia (7346) and IBS (7319) each fall within the range of DCs that the regulation says will not be separately evaluated and combined, they fall within the exception discussed in\nM21-1, Part V, Subpart iii, 6.1.b\nbecause effective May 19, 2024,\n38 CFR 4.114, DC 7346\nis evaluated using the criteria in\n38 CFR 4.114, DC 7203\n(stricture of the esophagus).  The 10-percent criteria for the two DCs do not overlap.  They do not compensate for the same disability or facet of disability, which is prohibited under\n38 CFR 4.14\n.  Note that under historical criteria, these DCs could not be separately evaluated and combined without pyramiding.\nV.iii.6.1.e\n.\nChanges to the Rating Schedule for the Digestive System\nThe schedule of ratings – digestive system,\n38 CFR 4.114\n, was amended effective May 19, 2024.  The final rule added and deleted DCs, and extensively changed diagnostic criteria.  The final rule also deleted regulations with obsolete or redundant guidance on ulcers (\n38 CFR 4.110\n) and post-gastrectomy syndrome (\n38 CFR 4.111\n).\nThe purpose of the digestive system updates was to ensure that the rating schedule uses current medical terminology and to provide updated more objective evaluation criteria.  The changes were\nnot\nintended as a liberalization.\nWhen evaluating a claim involving evaluation of a digestive disability that was pending on May 19, 2024, apply the guidance in\nM21-1, Part V, Subpart ii, 4.A.6.p\non applicability of revised rating schedule criteria.\nImportant\n:  In some instances, a digestive disorder may have been evaluated under analogous DC – whether using formal conventions for rating by analogy or not.  For example, prior to the current changes, gastroesophageal reflux disease (GERD) did not have its own DC.  The recommended DC for GERD in the past was 7346 (hiatal hernia).  It might appear on the\nCodesheet\nas “7399-7346” or just “7346.”  Now the DC is 7206.\nWhere a condition was previously rated by analogy but now has a specific DC, update the DC, but when considering the appropriate current evaluation, apply\n38 CFR 3.951(a)\n.  Do\nnot\nreduce the evaluation solely based on the changed criteria.  The evaluation can only be reduced when medical evidence establishes that the disability has actually improved.  Note that in the case of hiatal hernia and GERD, although the latter condition has its own DC the criteria for evaluating the two conditions is the same.  Hiatal hernia is rated as stricture of the esophagus (\n38 CFR 4.114, DC 7203\n), which uses identical criteria to those in\n38 CFR 4.114, DC 7206\n.\nReference\n:  For more information on protection and rating schedule changes, and reviewing evaluations after a rating schedule change, see\nM21-1, Part X, Subpart ii, 1.B.4\n.\n2\n.\nSC Considerations Involving Digestive Disabilities\nIntroduction\nThis topic contains information about SC considerations involving digestive disabilities, including\nconsidering circumstances of service when determining SC for gastrointestinal disorders\ntesting not required for SC for GERD\nestablishing SC for inguinal hernia\nSC and recurrence of hemorrhoids\nexample of analyzing recurrence of hemorrhoids\nother causes of liver damage\n, and\nfatty liver\n.\nChange Date\nOctober 17, 2024\nV.iii.6.2.a\n.\nConsidering Circumstances of Service When Determining SC for Gastrointestinal Disorders\nIf the issue is service connection (SC) for dysentery or other gastrointestinal disease, assign great weight to any service under the following conditions since these conditions may have been the etiological or aggravating factor:\ntropical service\nimprisonment or internment under unsanitary conditions, or\nfood deprivation.\nReference\n:  For more information on establishing presumptive SC for dysentery and other tropical diseases, see\n38 CFR 3.309(b)\n.\nV.iii.6.2.b\n.\nTesting Not Required for SC for GERD\nA diagnosis of GERD for SC purposes does not require documentation by medical imaging.\n38 CFR 4.114, DC 7206, Note (1)\nrequires “findings” to be documented by one of three types of imaging:  barium swallow, computed tomography (CT), or esophagogastroduodenoscopy.  This refers to documentation of esophageal stricture for evaluation purposes.  It does not define a sufficient diagnosis of GERD for SC purposes.\nNote\n:  A 10-percent evaluation for GERD can also be assigned pursuant to\n38 CFR 4.7\nwithout imaging to document esophageal stricture when the Veteran requires daily medications.\nV.iii.6.2.c\n.\nEstablishing SC for Inguinal Hernia\nDo not assume the preexistence of a hernia.  Determine preexistence on a factual basis.\nThe following conditions are sufficient bases for SC:\nin-service initial manifestation of hernial protrusion, and\nrecurrence during service, by aggravation, of a hernia previously surgically repaired.\nNote\n:  Operation for repair of a preexisting inguinal hernia is not necessarily evidence of aggravation.\nReference\n:  For information on the presumption of soundness at entrance into service, see\n38 CFR 3.304(b)\n.\nV.iii.6.2.d\n.\nSC and Recurrence of Hemorrhoids\nInitial awards of SC for hemorrhoids are governed by customary rules for SC included in\n38 CFR 3.303\n.\nAfter SC is initially established, unless the award of SC for hemorrhoids was in error, consider recurrences after a period of absence of hemorrhoids post-service to be associated with the SC condition rather than a nonservice-connected superseding condition.\nReference\n:  For more information on reversing an erroneous decision, see\n38 CFR 3.105(a)\n, and\nM21-1, Part X, Subpart ii, 5.A\n.\nV.iii.6.2.e\n.\nExample: Analyzing Recurrence of Hemorrhoids\nSituation\n:  SC is established for hemorrhoids first diagnosed during service. A 0-percent evaluation was assigned under\n38 CFR 4.114, DC 7336\n.\nTwo years after SC was granted for hemorrhoids, the Veteran filed a claim for increased evaluation.  Examination showed no hemorrhoids.  The diagnosis was “hemorrhoids, not shown.”  The 0-percent evaluation was continued.\nFive years later the Veteran filed a claim for an increased evaluation for hemorrhoids.  Records showed three instances of doctor visits in the last year for external hemorrhoids with thrombosis.  The Veteran reported a history of “old” problems with hemorrhoids and recent symptoms including bright red blood noted with defecation and discomfort with protracted sitting in his current job.  A Department of Veterans Affairs examination included a similar history and showed external hemorrhoids with thrombosis.  The diagnosis was “external hemorrhoids.”  Examination findings and findings in treatment records demonstrate the criteria for 10-percent evaluation in\n38 CFR 4.114, DC 7336\n.\nResult\n:  Assign a 10-percent evaluation.  The facts suggest that the SC hemorrhoids were non-disabling, or even absent, for an indeterminate period after SC was granted, and the Veteran’s current history in medical records and at the VA examination could suggest that the current hemorrhoids are due to a superseding post-service cause (protracted sitting at work).  However, the evidence does not prove that current hemorrhoids are due to a superseding cause or that SC was in error.  Pursuant to the principle in\nM21-1, Part V, Subpart iii, 6.2.d\n, after SC is initially established, consider hemorrhoids shown after a period of absence to be associated with the SC condition rather than due to a superseding post service cause unless the award of SC for hemorrhoids was clearly in error.  Do not return the examination for comment on that question.\nV.iii.6.2.f\n.\nOther Causes of Liver Damage\nThe table below describes recognized causes of liver damage and provides examples of each cause.\nCause of Liver Damage\nExample\nInfection\nVirus\nSystemic diseases\nLupus\nDrugs\nIsoniazid\nAcetaminophen\nPhenytoin\nToxic substances\nAlcohol\nV.iii.6.2.g\n.\nFatty Liver\nFatty liver, also called hepatic steatosis, is not a disability for which SC can be granted.  By itself it is simply considered an abnormal laboratory finding.\nReference\n:  For more information on abnormal laboratory findings discovered in STRs without a claim, see\nM21-1, Part V, Subpart ii, 3.C.1.d\n.\n3\n.\nHepatitis\nIntroduction\nThis topic contains information about hepatitis, including\ncategories of hepatitis recognized for rating purposes\ndiagnostic testing required for hepatitis\ninterpreting lab reports for\nhepatitis B (HBV)\n, and\nhepatitis C (HCV) after 1992\nrisk factors for HBV and HCV\ndevelopment for hepatitis risk factors\nconsidering drug abuse in hepatitis claims\nevaluating claims for increase for SC hepatitis awarded due to drug abuse\nconsidering in-service hepatitis findings\nrequesting exams and/or opinions for HBV or HCV\nreviewing hepatitis exams and opinions for sufficiency\n, and\nassigning a 0-percent evaluation for HCV\n.\nChange Date\nApril 21, 2025\nV.iii.6.3.a\n.\nCategories of Hepatitis Recognized for Rating Purposes\nThere are three main categories of viral hepatitis recognized for rating purposes.  The table below describes each type of hepatitis and explains the transmission and prognosis for each.\nType of Hepatitis\nTransmission\nPrognosis\nhepatitis A virus (HAV), previously called infectious hepatitis\nfecal-oral route\nAcute—seldom severe and does not leave residuals.\nNote\n:  In order to award SC, there must be evidence of chronic residuals related to the hepatitis A infection.\nhepatitis B virus (HBV), previously called serum hepatitis\nblood products\nsexual contact\nAcute in 90-95 percent of cases, but acute disease can be severe and result in death.\nChronic in 5-10 percent of cases.\nCirrhosis and liver cancer may develop.\nA vaccine to prevent HBV infection is available.\nhepatitis C virus (HCV), previously called non-A non-B hepatitis\ninfected blood\nClinically asymptomatic acute disease.\nChronic disease develops in 80 percent of cases following acute phase.\nDiagnosis is generally made incidentally many years later.\nNote\n:  Infectious hepatitis is common throughout the world and was especially prevalent during World War II following administration of the yellow fever vaccine in 1942 and in the Mediterranean Theater.\nReference\n:  For more information on risk factors for HBV and HCV, see\nM21-1, Part V, Subpart iii, 6.3.e\n.\nV.iii.6.3.b\n.\nDiagnostic Testing Required for Hepatitis\nSC for hepatitis requires blood serology testing to establish a diagnosis and identify the type of hepatitis present.  Liver function tests (LFTs) are necessary to assess the severity of the disease.\nNotes\n:\nThe rating decision should always specify the type of hepatitis for which SC is awarded.\nSerological tests\ndetermine the presence of antigens and antibodies to the specific virus.  The presence of antibodies to the specific virus indicates the infection is present.\nThe table below describes types of serological testing required to confirm a diagnosis for each type of hepatitis.\nType of Hepatitis\nSerology or Other Testing Required\nAdditional Notes\nHAV\nanti-HAV (antibodies to hepatitis A virus)\nAnti-HAV are present in the blood one month after the acute illness and persist for life.\nSerological blood testing showing the presence of anti-HAV indicates a past acute infection.\nHBV\nanti-HBsAg (hepatitis B surface antigen) is present during the acute phase.\nHBsAg that persists more than three to six months indicates probable chronic disease or carrier status.\nA positive Australian antigen test is sufficient to confirm HBV.\nHBV has two antigens, a surface antigen and a core antigen\nHBsAg, and\nHBcAg (hepatitis B core antigen).\nConsequently, two types of antibodies appear in the blood\nanti-HBs (antibodies to the surface antigen), and\nanti-HBc (antibodies to the core antigen).\nHCV\nEIA (enzyme immunoassay) or ELISA (enzyme linked immunosorbent assay, also called Western blot) is the first test.\nIf EIA or ELISA is positive, RIBA (recombinant immunoblot assay) is needed to confirm the diagnosis of chronic HCV.\nIn lieu of EIA/ELISA followed by RIBA, a positive test for HCV RNA (hepatitis C viral ribonucleic acid) is sufficient by itself to confirm a diagnosis of HCV.\nHCV RNA results can be\nqualitative (positive or negative), or\nquantitative (number of copies per milliliter (ml)).\nThe presence of anti-HCV (including EIA or ELISA) is\nnot\nsufficient for a diagnosis of chronic HCV because it can be present in other diseases.\nNote\n:  Liver biopsy, ultrasound, and CT scan tests can detect damage to the liver but will not identify the type of infection.\nV.iii.6.3.c\n.\nInterpreting Lab Reports for HBV\nThe table below provides an example of a laboratory interpretation of serology test results for HBV.\nTest\nResults\nInterpretation\nExample 1\nHBsAg\nnegative\nsusceptible to infection\nanti-HBc\nnegative\nsusceptible to infection (no HBV)\nanti-HBs\nnegative\nno history of HBV\nExample 2\nHBsAg\nnegative\nimmune\nanti-HBc\nnegative or positive\nimmune\nanti-HBs\npositive\nExample 3\nHBsAg\npositive\nacute infection\nanti-HBc\npositive\nImmunoglobulin M (IgM) anti-HBc\npositive\nacute infection\nanti-HBs\nnegative\nExample 4\nHBsAg\npositive\nchronic infection\nanti-HBc\npositive\nIgM anti-HBc\nnegative\nchronic infection\nanti-HBs\nnegative\nV.iii.6.3.d\n.\nInterpreting Lab Reports for HCV After 1992\nThe table below provides an example of a laboratory interpretation of serology testing for HCV for testing performed after 1992.\nTests\nResults\nInterpretation\nanti-HCV\npositive (probable chronic hepatitis)\nneed to verify diagnosis\nEIA\npositive\nsupplemental test required\nRIBA\npositive\ndiagnostic\nHCVRNA\nfollow-up of chronic HCV\nnot needed for rating\nV.iii.6.3.e\n.\nRisk Factors for HBV and HCV\nRisk factors for the development of HBV and HCV are similar.  The table below describes the medically recognized risk factors for HBV and HCV infection, provides transmission information concerning those risk factors, and includes tips for confirming the risk factors.\nNote\n:  Resolve reasonable doubt under\n38 CFR 3.102\nin favor of the Veteran when the evidence favoring risk factor(s) in service is equal to the evidence favoring risk factor(s) before or after service.\nRisk Factor\nTransmission Information\nRating Tips\ntransfusion of blood or blood product\nbefore 1992 for HCV, or\nbefore 1975 for HBV\norgan transplant before 1992, or\nhemodialysis\nBlood donor screening for HCV was not available until 1989 when HCV was identified.\nIn 1992, more effective screening of blood became possible for HCV.\nIf blood transfusion is a claimed risk factor, obtain the relevant hospital records from service, if possible.\nLook for evidence of blood transfusions in surgical reports, especially the\nanesthesia sheet\nsurgical record\noperative clinical records, or\npost-operative clinical notes.\ntattoos\nbody piercing, and\nacupuncture with non-sterile needles\ntransmitted through the use of unsterilized equipment\nReview for indications of tattoos or piercings on induction and separation exams to help determine whether tattooing or piercing took place in service.\nintravenous drug use\ntransmitted through the use of shared instruments\nRecords of drug treatment may reflect the type of drug abuse.\nhigh-risk sexual activity\nTransmission risk is relatively low but increases with multiple sexual partners.\nPeriodic health assessments or records of treatment for sexually transmitted diseases may document a history of high-risk sexual activity or multiple sexual partners.\nintranasal cocaine use\ntransmitted through the use of shared instruments\nRecords of drug treatment may reflect the type of drug abuse.\naccidental exposure to blood by percutaneous exposure or on mucous membranes\ncommon for the following:\nhealth care workers\ncombat medics, and\ncorpsmen\nConsider service department or other records reflecting occupational history.\nsharing of\ntoothbrushes, or\nshaving razors\ntransmitted through direct percutaneous exposure to blood\nThis type of in-service exposure will not generally be documented in service records. Consider buddy statements in the context of the entire evidence picture pertaining to risk factors.\nimmunization with a jet air gun injector\none\ndocumented case of HBV transmission\nDespite the lack of any scientific evidence to document transmission of HCV with air gun injectors, it is biologically possible.\nA medical report linking hepatitis to air gun injectors must include a full discussion of all potential modes of transmission and a rationale as to why the examiner believes the air gun injector was the source for the hepatitis infection.\nReference\n:  For more information on development for and the concession of in-service risk factors associated with HCV, see\nAndrews v. McDonough\n, 34 Vet.App. 151 (2021).\nV.iii.6.3.f\n.\nDevelopment for Hepatitis Risk Factors\nAs\nVA Form 21-526EZ, Application for Disability Compensation and Related Compensation Benefits\n, does not inform the claimant to submit evidence of hepatitis risk factors, development for risk factors is required in every hepatitis claim, even when hepatitis is diagnosed in service.  Development is necessary to determine if pre- and post-service risk factors are present as well as to ensure that the risk factor is not substance abuse either before or during service.\nRegardless of what claim form the Veteran submits, development for risk factors is required if the complete risk factor history has not already been provided.  If risk factor history is not of record send a risk factor development letter to the Veteran.\nReferences\n:  For more information on\nSC for hepatitis associated with drug use, see\nM21-1, Part V, Subpart iii, 6.3.g\n, and\nexaminations and medical opinions in hepatitis claims, see\nM21-1, Part V, Subpart iii, 6.3.j\n.\nV.iii.6.3.g\n.\nConsidering Drug Abuse in Hepatitis Claims\nIf one of the risk factors for hepatitis is intravenous or intramuscular drug use, or intranasal cocaine use, do\nnot\nautomatically assume the substance abuse is the cause of hepatitis and deny the claim on that basis.\nFollow the steps in the table below when considering a claim for SC for hepatitis in which injection drug or intranasal cocaine use is a confirmed in-service risk factor.\nStep\nAction\n1\nReview for all risk factors of hepatitis in addition to the drug use.\n2\nIf injection drug or intranasal cocaine use is the only confirmed in-service risk factor present, then deny SC. If other in-service risk factors are found in addition to injection drug or intranasal cocaine use, go to Step 3.\n3\nRequest a medical opinion to determine which confirmed in-service risk factor is at least as likely as not the cause of the hepatitis infection.\n4\nUse the table below to determine how to proceed with the medical opinion.\nIf the medical opinion …\nThen …\nstates that drug use is the cause of the hepatitis infection\ndeny the claim for SC for hepatitis.\ngives greater or equal weight to another confirmed in-service risk factor\nresolve reasonable doubt in the Veteran’s favor, and\naward SC.\nis unable to state which risk factor is more likely than not to be the cause of the hepatitis\nweigh all evidence, and\napply the reasonable doubt doctrine if the evidence is found to be in equipoise.\nReference\n:  For more information on examiner statements that an opinion would be speculative, see\nM21-1, Part IV, Subpart i, 3.A.1.q\n.\nReference\n:  For more information on considering claims for SC based on drug use, see\n38 CFR 3.301(c)(3)\n, and\nM21-1, Part X, Subpart iv, 1.D.2\n.\nV.iii.6.3.h\n.\n﻿  Evaluating Claims for Increase for SC Hepatitis Awarded Due to Drug Abuse\nFollow the steps in the table below to determine the appropriate actions to take in a claim for increase when SC was previously awarded but the only apparent risk factor in service was drug abuse.\nStep\nAction\n1\nWas SC for hepatitis due to drug abuse awarded by rating decision on or before October 31, 1990?\nIf\nyes\n, then continue the finding of SC for hepatitis as the award of SC was proper based on regulations and procedures at that time. Go to Step 5.\nIf\nno\n, then go to Step 2.\n2\nDoes the evidence clearly show that the hepatitis is due to in-service drug abuse?\nIf\nyes\n, go to Step 4.\nIf\nno\n, go to Step 3.\n3\nIf SC was awarded but there is no evidence clearly linking the hepatitis to drug abuse or if there were multiple risk factors in service, one of which was drug abuse, and no prior opinion was obtained, request a medical opinion to determine whether the hepatitis is due to the drug abuse.\nIf the resulting opinion\nclearly links hepatitis to drug abuse, go to Step 4.\ncannot resolve whether hepatitis is due to drug abuse or another in-service risk factor, or the hepatitis is attributed to another non-drug abuse in-service risk factor, then\nresolve reasonable doubt in favor of the Veteran and continue the finding of SC, and\naward an increased evaluation for hepatitis if the medical evidence otherwise shows the increase is warranted.\n4\nIf the evidence clearly shows that the hepatitis is due to in-service drug abuse and SC was awarded by rating decision after October 31, 1990, determine whether the award of SC is protected per\n38 CFR 3.957\n.\nIf SC. is protected, go to Step 5.\nIf SC is not protected, then propose to sever SC per\n38 CFR 3.105(a)\n.\n5\nIf SC was properly established for hepatitis due to drug abuse by rating decision on or before October 31, 1990, and/or if the award of SC for hepatitis is protected, do not award an increased evaluation for hepatitis due to drug abuse.\nNotes\n:\nThe Omnibus Reconciliation Act of 1990 (\nPublic Law 101-508 Section 8052\n) prohibited the grant of SC for disability or death resulting from alcohol or drug abuse for claims filed after October 31, 1990.\nVAOPGCPREC 2-1998\nfound that an increased evaluation may not be awarded when SC was previously properly established as due to drug abuse by rating decision on or before October 31, 1990.\nV.iii.6.3.i\n.\nConsidering In-Service Hepatitis Findings\nWhen a Veteran submits a claim for SC of hepatitis, assess the lay evidence, service treatment records (STRs), and current medical records to ascertain whether a current disability, an in-service event or injury, and an indication of an association are present as required in\n38 CFR 3.159(c)(4)\nprior to requesting examination and/or medical opinion.\nUse the table below to determine the proper rating action for in-service findings related to hepatitis.\nIf STRs show ...\nThen ...\ndiagnosis of non-specific hepatitis and SC is claimed many years later\nrequest an exam with serology testing and LFTs (if not already of record) and opinion to determine if a relationship exists between the episode of hepatitis in service and the current type of hepatitis unless there is sufficient evidence of a clearly-established diagnosis and continuous symptoms present to satisfy the nexus standard under\n38 CFR 3.303(b)\n.\nlaboratory findings confirming HAV or HBV\nSC for HAV is not warranted as HAV is an acute condition.\nConsider SC for HBV if a chronic disability is present and linked to the in-service finding and/or risk factors.\nConsider SC for HCV if a medical opinion links the condition to the confirmed in-service findings and/or risk factors.  However, do not automatically grant SC for HCV.  The lab findings in service alone do not show HCV in service or allow a conclusion that HCV was incurred in service.  Each type of hepatitis can be acquired at different times and through different means.\na diagnosis of non-A, non-B hepatitis (old name for HCV) and the current medical evidence confirms a diagnosis of HCV\nSC is likely warranted.\nIf medical evidence establishes the presence of continuous symptoms since service, then award SC.\nIf evidence of continuous symptoms since service is not present, request a nexus opinion.\nnon-specific hepatitis and current evidence shows HCV\nor\nchronic HBV only\nHCV or chronic HBV\nmay\nwarrant SC based on reasonable doubt. Request a medical opinion and any necessary diagnostic testing to confirm the diagnosis.\nReference\n:  For more information on diagnostic testing required for hepatitis, see\nM21-1, Part V, Subpart iii, 6.3.b\n.\nnon-specific hepatitis and current evidence shows HCV\nor\nchronic HBV as well as a history of HAV\na medical opinion is necessary to determine whether the current disability is a result of the non-specific hepatitis diagnosed in service.\nV.iii.6.3.j\n.\nRequesting Exams and/or Opinions for HBV or HCV\nFollow the steps in the table below when requesting an examination and/or opinion for HCV or chronic HBV.\nStep\nAction\n1\nIdentify and request the examiner review of all relevant evidence in the claims folder.\n2\nList any risk factors identified by the Veteran.\n3\nIdentify all risk factors confirmed by the evidence in the claims folder, whether claimed by the Veteran or not.\nImportant\n:  In addition to in-service risk factors, ensure that all documented pre- and post-service risk factors are noted in the exam request.\n4\nRequest\nHepatitis, Cirrhosis And Other Liver Conditions Disability Benefits Questionnaire\n.\n5\nRequest a medical opinion about the relationship between the current HBV or HCV infection and confirmed or supported risk factor(s).\n6\nNotify the examiner that a positive nexus opinion, if warranted, should take only confirmed risk factors as shown by the objective evidence of record into consideration.\nReferences\n:  For more information on\nconfirming risk factors, see\nM21-1, Part V, Subpart iii, 6.3.e\n, and\nevaluating evidence, see\nM21-1, Part V, Subpart ii, 1.A\n.\nV.iii.6.3.k\n.\nReviewing Hepatitis Exams and Opinions for Sufficiency\nReview the examination or opinion to ensure sufficiency and return insufficient examinations when warranted.  Common reasons for insufficient examinations are\nlack of proper confirmatory testing to support the diagnosis\nfailure to include complete clinical findings and symptoms in the report\nfailure to address all known risk factors in the opinion\nopinions linking HCV or chronic HBV to a risk factor that is not confirmed in the evidence of record, and\nopinions improperly linking HCV or chronic HBV to a risk factor that is not medically recognized as a source of infection.\nV.iii.6.3.l\n.\nAssigning a 0-Percent Evaluation for HCV\nTo assign an evaluation for HCV (\n38 CFR 4.114, DC 7354\n) use the criteria in\n38 CFR 4.114, DC 7345\n(chronic liver disease without cirrhosis).\nA 0-percent evaluation should only be assigned for HCV when the condition is asymptomatic with a previous history of liver disease.\nUse the table below to determine when it is appropriate to assign a 0-percent evaluation for HCV.\nIf medical evidence shows ...\nThen a 0-percent disability evaluation is ...\neven mild symptoms related to HCV infection\nnot appropriate because the Veteran is symptomatic.\nthere is evidence of liver damage on LFTs, liver biopsy, or other testing\nnot appropriate because this means the infection is not\nhealed\n.\nHCV has responded to therapy to the extent that RNA test results are negative, and the Veteran is now asymptomatic with no evidence of liver damage\nappropriate. However, HCV remains dormant in the system and may flare up again later.\nReference\n:  For more information on evaluation of HCV, see\n38 CFR 4.114, DC 7354\n.\n<-- Previous Section\nNext Section -->\nTo Top",
  "content_html": "<div class=\"article-content\">\n<div compile-custom=\"article.content\" ng-aria=\"articleContent\"><p class=\"ng-scope\"></p><p class=\"ng-scope\" style=\"text-align: right\"><span style=\"font-size: 11px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a articleid=\"554400000014520\" articlename=\"M21-1, Part V, Subpart iii, Chapter 5 - Cardiovascular System Conditions\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014520/M21-1-Part-V-Subpart-iii-Chapter-5-Cardiovascular-System-Conditions\">&lt;-- Previous Section</a>  <a articleid=\"554400000180593\" articlename=\"M21-1, Part V, Subpart iii, Chapter 7 - Genitourinary Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180593/M21-1-Part-V-Subpart-iii-Chapter-7-Genitourinary-Disabilities\">Next Section --&gt;</a></span></span></p><h2 class=\"ng-scope\"><a id=\"top\" name=\"top\"><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">Overview</span></span></a></h2><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">In This Chapter</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">This chapter contains the following topics:</span></span></div><div></div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width: 495px; border-spacing: 1px; border-collapse: revert;\" summary=\"Column 1 has the topic number and column 2 has the topic title.\"><thead><tr><th scope=\"col\" style=\"width: 86px; padding: 1px;\"><div style=\"text-align: center\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong><span style=\"display: none\"> </span>Topic</strong></span></span></div></th><th scope=\"col\" style=\"width: 333px; padding: 1px;\"><div style=\"text-align: center\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong>Topic Name</strong></span></span></div></th></tr></thead><tbody><tr><td style=\"width: 86px; padding: 1px;\"><div align=\"center\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"font-size: 14px\">1 </span></span></div></td><td style=\"width: 333px; vertical-align: middle; padding: 1px;\"><div><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"#1\" target=\"_self\"><span style=\"font-size: 14px\">Assigning Evaluations for Digestive Disabilities</span></a></span></div></td></tr><tr><td style=\"width: 86px; text-align: center; padding: 1px;\"><div><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"font-size: 14px\">2</span></span></div></td><td style=\"width: 333px; vertical-align: middle; padding: 1px;\"><div><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"#2\" target=\"_self\"><span style=\"font-size: 14px\">Service Connection (SC) Considerations Involving Digestive Disabilities</span></a></span></div></td></tr><tr><td style=\"width: 87px; padding: 1px;\"><div align=\"center\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"font-size: 14px\">3</span></span></div></td><td style=\"width: 333px; padding: 1px;\"><div><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"#3\" target=\"_self\"><span style=\"font-size: 14px\">SC and Evaluation Considerations Involving Hepatitis</span></a></span></div></td></tr></tbody></table><div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">       </span></span><br/> </div><h2 class=\"ng-scope\"><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">1<a id=\"1\" name=\"1\">.  </a>Assigning Evaluations for Digestive Disabilities</span></span></h2><p class=\"ng-scope\"> <br/> </p><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">This topic contains information about assigning evaluations for digestive disabilities, including</span></span></div><ul><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#1a\" target=\"_self\"><span style=\"font-size: 14px\">regulatory framework for assigning evaluations for digestive disabilities</span></a></span></div></li><li><div><a href=\"#1b\" target=\"_self\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">prohibition of separate evaluations for certain coexisting digestive disabilities</span></span></a></div></li><li><div><a href=\"#1c\" target=\"_self\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">evaluating coexisting digestive disabilities that cannot be separately evaluated</span></span></a></div></li><li><div><a href=\"#1d\" target=\"_self\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">example of evaluating coexisting digestive disabilities</span></span></a><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">, and</span></span></div></li><li><div><a href=\"#1e\" target=\"_self\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">changes to the rating schedule for the digestive system</span></span></a><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">May 20, 2024</span></span></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.6.1.a<a id=\"1a\" name=\"1a\">.</a>  Regulatory Framework for Assigning Evaluations for Digestive Disabilities</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div class=\"MsoBlockText\"><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">Disabilities of the digestive system are rated using</span></span></div><ul><li class=\"MsoBlockText\"><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR52ba1b312b58845/section-4.112\" target=\"_blank\">38 CFR 4.112</a> (weight loss and nutrition)</span></span></li><li><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR52ba1b312b58845/section-4.113\" target=\"_blank\">38 CFR 4.113</a> (coexisting abdominal conditions), and</span></span></div></li><li><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR52ba1b312b58845/section-4.114\" target=\"_blank\">38 CFR 4.114</a> (the schedule of ratings for the digestive system).</span></span></div></li></ul><div class=\"MsoBlockText\"><a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR52ba1b312b58845/section-4.112\" style=\"font-family: Arial, Helvetica, sans-serif; font-size: 14px;\" target=\"_blank\">38 CFR 4.112</a><span style=\"font-family: Arial, Helvetica, sans-serif; font-size: 14px;\"> defines terms used in diagnostic criteria in </span><a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR52ba1b312b58845/section-4.114\" style=\"font-family: Arial, Helvetica, sans-serif; font-size: 14px;\" target=\"_blank\">38 CFR 4.114</a><span style=\"font-family: Arial, Helvetica, sans-serif; font-size: 14px;\"> that involve weight and nutrition. </span></div><div class=\"MsoBlockText\"></div><div class=\"MsoBlockText\"><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR52ba1b312b58845/section-4.113\" target=\"_blank\">38 CFR 4.113</a> provides a general warning that certain coexisting digestive conditions (those listed in the prefatory instruction in <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR52ba1b312b58845/section-4.114\" target=\"_blank\">38 CFR 4.114</a>) cannot be separately evaluated without pyramiding. </span></span></div><div class=\"MsoBlockText\"></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR52ba1b312b58845/section-4.114\" target=\"_blank\">38 CFR 4.114</a> contains diagnostic codes (DCs) and associated criteria for disabilities of the digestive system.  It also contains a general principle that certain listed DCs cannot be separately evaluated and combined.  </span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.6.1.b<a id=\"1b\" name=\"1b\">.</a>  Prohibition of Separate Evaluations for Certain Coexisting Digestive Disabilities</span></span></h3></td><td style=\"height: 8px; width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div class=\"MsoBlockText\"><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=678e1a0b35110a17aae704e69f2701f2&amp;mc=true&amp;node=se38.1.4_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.114</a> prohibits assigning separate evaluations for certain coexisting digestive disabilities.  The purpose of the prohibition, as is further explained in <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR52ba1b312b58845/section-4.113\" target=\"_blank\">38 CFR 4.113</a> and <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-A/section-4.14\" target=\"_blank\">38 CFR 4.14</a>, is so that digestive disabilities, particularly within the abdomen, with closely related overlapping manifestations will not be combined under <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-A/section-4.25\" target=\"_blank\">38 CFR 4.25</a>, resulting in extra compensation for the same disability or facet of disability.</span></span></div><div class=\"MsoBlockText\"></div><div class=\"MsoBlockText\"><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">Assignment of separate evaluations for any combination of the following DCs is prohibited: </span></span></div><ul><li class=\"MsoBlockText\"><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">7301 through 7329</span></span></li><li class=\"MsoBlockText\"><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">7331</span></span></li><li class=\"MsoBlockText\"><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">7342</span></span></li><li class=\"MsoBlockText\"><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">7345 through 7350</span></span></li><li class=\"MsoBlockText\"><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">7352, and</span></span></li><li class=\"MsoBlockText\"><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">7355 through 7357.</span></span></li></ul><div class=\"BulletText1\" style=\"text-indent: 0in;\"><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><b><i>Exceptions</i></b>:  Effective May 19, 2024, <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR52ba1b312b58845/section-4.114\" target=\"_blank\">38 CFR 4.114</a> does not categorically prohibit evaluating hiatal hernia separately from another condition in the above list, as long as the specific evaluations do not pyramid under <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-A/section-4.14\" target=\"_blank\">38 CFR 4.14</a>.  This is because as of that date, hiatal hernia (<a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=678e1a0b35110a17aae704e69f2701f2&amp;mc=true&amp;node=se38.1.4_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.114, DC 7346</a>) is evaluated using the diagnostic criteria for esophageal stricture (<a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=678e1a0b35110a17aae704e69f2701f2&amp;mc=true&amp;node=se38.1.4_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.114, DC 7203</a>), which is not included in the listed DCs.    </span></span></div><div class=\"BulletText1\" style=\"text-indent: 0in;\"></div><div class=\"BulletText1\" style=\"text-indent: 0in;\"><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">Additionally, some DCs provide instructions to rate residuals <i>not addressed in the diagnostic criteria</i> under another DC.  <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=678e1a0b35110a17aae704e69f2701f2&amp;mc=true&amp;node=se38.1.4_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.114, DC 7319</a> (irritable bowel syndrome (IBS)) contains a note that says, “Evaluate other symptoms of a functional digestive disorder, not encompassed by this diagnostic code, under the appropriate diagnostic code, to include gastrointestinal dysmotility syndrome (DC 7356), following the general principles of § 4.14 and this section.”  </span></span></div><div class=\"BulletText1\" style=\"text-indent: 0in;\"></div><div class=\"BulletText1\" style=\"text-indent: 0in;\"><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">When the primary DC for the diagnosis, and a DC for rating other residuals not encompassed in the primary DC are both listed in <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=678e1a0b35110a17aae704e69f2701f2&amp;mc=true&amp;node=se38.1.4_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.114</a>, the evaluations <i>can</i> be combined on a case-by-case basis as long as the symptoms used to provide each evaluation do not pyramid under <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-A/section-4.14\" target=\"_blank\">38 CFR 4.14</a>.  </span></span></div><div></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><b><i>Important</i></b>:</span></span></div><ul><li><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">Where disabilities that fall within the range of DCs above cannot be separately evaluated and included in a combined evaluation, a single evaluation will be assigned as provided in <a href=\"#1c\" target=\"_self\">M21-1, Part V, Subpart iii, 6.1.c</a>.  As explained in that block, elevation of the evaluation may be appropriate.</span></span></div></li><li><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">When separately evaluating and combining DCs is prohibited under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=678e1a0b35110a17aae704e69f2701f2&amp;mc=true&amp;node=se38.1.4_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.114</a>, the <i>Codesheet</i> must still reflect each service-connected (SC) disability.  </span></span></div></li></ul><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><b><i>Notes</i></b>:</span></span></div><ul><li><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">Separately evaluating and combining 7200-series DCs (such as Barrett’s esophagus) with a 7300-series DC (such as IBS or Crohn’s disease) is not categorically prohibited by <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=678e1a0b35110a17aae704e69f2701f2&amp;mc=true&amp;node=se38.1.4_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.114</a>. </span></span></div></li><li><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">Similarly, separately evaluating and combining multiple 7200-series DCs is not categorically prohibited. </span></span></div></li><li><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">Whenever considering DCs that are not included in the <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=678e1a0b35110a17aae704e69f2701f2&amp;mc=true&amp;node=se38.1.4_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.114</a> list above, always carefully consider whether specific diagnostic criteria will compensate the same facet of disability and therefore violate <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-A/section-4.14\" target=\"_blank\">38 CFR 4.14</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.6.1.c<a id=\"1c\" name=\"1c\">.</a>  Evaluating Coexisting Digestive Disabilities That Cannot Be Separately Evaluated</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">Under <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=2a53e1b0a72d2663bf1e9cacf30abff9&amp;mc=true&amp;node=se38.1.4_1113&amp;rgn=div8https://www.ecfr.gov/cgi-bin/text-idx?SID=2a53e1b0a72d2663bf1e9cacf30abff9&amp;mc=true&amp;node=se38.1.4_1113&amp;rgn=div8\" target=\"_blank\">38 CFR 4.113</a> and <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=678e1a0b35110a17aae704e69f2701f2&amp;mc=true&amp;node=se38.1.4_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.114</a> when there are coexisting digestive disabilities for which multiple evaluations cannot be assigned</span></span></div><ul><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">a single rating will be assigned under the DC which reflects the predominant disability, and</span></span></div></li><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">that evaluation will be elevated to the next higher evaluation when the severity of the overall disability warrants it.</span></span></div></li></ul><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">The Veterans Benefits Management System – Rating (VBMS-R) Evaluation Builder is programmed to appropriately apply the provisions of <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=678e1a0b35110a17aae704e69f2701f2&amp;mc=true&amp;node=se38.1.4_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.114</a> <strong><em>but</em></strong> it is critical that</span></span></div><ul><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">the user input the symptoms that support the elevation, and</span></span></div></li><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">the symptoms coincide with the criteria listed in the rating schedule.</span></span></div></li></ul><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">For instructions on proper application of the <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=678e1a0b35110a17aae704e69f2701f2&amp;mc=true&amp;node=se38.1.4_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.114</a> provision on assigning an evaluation in cases of multiple qualifying coexisting digestive disabilities see the table below.</span></span></div><div></div><div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width: 510px; border-spacing: 1px; border-collapse: revert;\" summary=\"This is a step-action table.  Column 1 is the step number and column 2 provides instructions on proper application of the 38 CFR 4.114 provision on assigning an evaluation in cases of multiple qualifying coexisting digestive disabilities\" width=\"510\"><thead><tr><th scope=\"col\" style=\"width: 72px; padding: 1px;\"><div align=\"center\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\"><strong>Step</strong></span></span></div></th><th scope=\"col\" style=\"width: 438px; padding: 1px;\"><div align=\"center\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\"><strong>Action</strong></span></span></div></th></tr></thead><tbody><tr><td style=\"width: 72px; vertical-align: top; padding: 1px;\"><div align=\"center\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">1</span></span></div></td><td style=\"width: 438px; padding: 1px;\"><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">Determine which of the coexisting digestive conditions is the predominant disability. </span></span></div><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\"> </span></span></div><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\"><strong><em>Important</em></strong>: </span></span></div><ul><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">To determine the predominant disability, determine the evaluation each condition would support on its own.  The condition that has the highest disability evaluation is the predominant disability.</span></span></div></li><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">If the same evaluation would be assigned to each, go through the analysis in the steps, alternatively treating each condition as the predominant one to see if one alternative provides a more advantageous outcome to the Veteran. </span></span></div></li></ul></td></tr><tr><td style=\"width: 72px; vertical-align: top; padding: 1px;\"><div align=\"center\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">2</span></span></div></td><td style=\"width: 438px; padding: 1px;\"><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">Determine if there are symptoms of the non-predominant disability that do not overlap with those of the predominant disability.</span></span></div><ul><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">If <em>yes</em>, go to Step 3.</span></span></div></li><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\"><span style=\"font-size: 14px\">If <em>no</em>, go to Step 4.</span></span></span></div></li></ul></td></tr><tr><td style=\"width: 72px; vertical-align: top; padding: 1px;\"><div align=\"center\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">3</span></span></div></td><td style=\"width: 438px; padding: 1px;\"><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">Reevaluate the predominant disability but this time also consider the non-overlapping symptoms of the non-predominant disability. </span></span></div><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\"> </span></span></div><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\"><strong><em>Important</em></strong>:  The non-overlapping symptoms must support a higher evaluation when applied to the DC criteria being utilized for the predominant disability. </span></span></div><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\"> </span></span></div><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">Determine if the resultant evaluation is higher than the evaluation for the symptoms of the predominant disability alone (as derived in Step 1).</span></span></div><ul><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">If <em>yes</em>, go to Step 5.</span></span></div></li><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">If <em>no</em>, go to Step 4.</span></span></div></li></ul></td></tr><tr><td style=\"width: 72px; vertical-align: top; padding: 1px;\"><div align=\"center\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">4</span></span></div></td><td style=\"width: 438px; padding: 1px;\"><ul><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">Rate the coexistent disabilities together under the rating criteria for the predominant disability <em>without elevation</em> to the next higher evaluation.</span></span></div></li><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">No further action necessary. </span></span></div></li></ul></td></tr><tr><td style=\"width: 72px; vertical-align: top; padding: 1px;\"><div align=\"center\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">5</span></span></div></td><td style=\"width: 438px; padding: 1px;\"><ul><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">Rate the coexistent disabilities together under the rating criteria for the predominant disability and elevate to the next higher evaluation.</span></span></div></li><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">No further action necessary. </span></span></div></li></ul></td></tr></tbody></table></div><div></div><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\"><strong><em>Important</em></strong>:  The “next higher level of evaluation” is the lowest evaluation specified in the DC for the predominant disability <em>that provides greater compensation than the evaluation derived in Step 1</em> (the evaluation that would be supported by only the symptoms of the predominant disability without the symptoms of the lesser disability).  <em><strong>Do not simply add 10 percent</strong></em>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.6.1.d<a id=\"1d\" name=\"1d\">.</a>  Example:  Evaluating Coexisting Digestive Disabilities</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><b><i>Situation</i></b>:  A Veteran has two coexisting digestive disabilities:</span></span></div><ul><li class=\"BulletText1\"><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">peptic ulcer disease meeting the criteria for a 20-percent evaluation under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=678e1a0b35110a17aae704e69f2701f2&amp;mc=true&amp;node=se38.1.4_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.114, DC 7304</a> (two episodes of abdominal pain lasting for three consecutive days in duration in the past 12 months managed by daily prescribed medication), and</span></span></li><li class=\"BulletText1\"><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">ulcerative colitis of the large bowel, meeting the criteria for a 30-percent evaluation under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=678e1a0b35110a17aae704e69f2701f2&amp;mc=true&amp;node=se38.1.4_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.114, DC 7323</a>, which is evaluated using the criteria for Crohn’s disease or undifferentiated inflammatory bowel disease in <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=678e1a0b35110a17aae704e69f2701f2&amp;mc=true&amp;node=se38.1.4_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 3.114, DC 7326</a> (mild disease managed with oral and topical agents other than immunosuppressants or other biologic agents, and characterized by recurrent abdominal pain with 3 or fewer daily episodes of diarrhea and minimal signs of toxicity including infrequent low grade fever). </span></span></li></ul><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><b><i>Result</i></b>:  <i>Separate</i> evaluations for the peptic ulcer disease and ulcerative colitis are <i>not</i> permitted under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=678e1a0b35110a17aae704e69f2701f2&amp;mc=true&amp;node=se38.1.4_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.114</a>.  A single 30-percent evaluation under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=678e1a0b35110a17aae704e69f2701f2&amp;mc=true&amp;node=se38.1.4_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.114, DC 7323</a> would be assigned. </span></span></div><div></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><b><i>Explanation</i></b>:  Ulcerative colitis represents the predominant disability picture as it supports the higher evaluation on its own.    </span></span></div><div></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">There are no non-overlapping symptoms of peptic ulcer disease to establish any of the criteria supporting the next higher 60-percent evaluation for ulcerative colitis:  moderate inflammatory bowel disease that is managed on an outpatient basis with immunosuppressants or other biologic agents; and is characterized by recurrent abdominal pain, four to five daily episodes of diarrhea; and intermittent signs of toxicity such as fever, tachycardia, or anemia.  Therefore, the coexistent disabilities must be rated together under the rating criteria for the predominant disability <i>without elevation</i> to the next higher 60-percent evaluation.</span></span></div><div></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><b><i>Situation</i></b>:  A Veteran has two coexisting digestive conditions:</span></span></div><ul><li><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">IBS, meeting the criteria for a 10-percent evaluation under <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=409c267ffb758e5b31de5f5cb2da025a&amp;mc=true&amp;node=se38.1.4_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.114, DC 7319</a> (abdominal pain related to defecation at least once during the previous three months; and two or more of the following: (1) change in stool frequency, (2) change in stool form, (3) altered stool passage (straining and/or urgency), (4) mucorrhea, (5) abdominal bloating, or (6) subjective distension), and</span></span></li><li><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">hiatal hernia, meeting the criteria for a 10-percent evaluation under <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=409c267ffb758e5b31de5f5cb2da025a&amp;mc=true&amp;node=se38.1.4_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.114, DC 7346</a>, which is rated as stricture of the esophagus under <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=409c267ffb758e5b31de5f5cb2da025a&amp;mc=true&amp;node=se38.1.4_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.114, DC 7203</a> (documented history of esophageal stricture(s) that requires daily medications to control dysphagia otherwise asymptomatic).</span></span></div></li></ul><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><b><i>Result</i></b>:  Effective May 19, 2024, <i>separate</i> evaluations for IBS and hiatal hernia are permitted under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=678e1a0b35110a17aae704e69f2701f2&amp;mc=true&amp;node=se38.1.4_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.114</a>.    </span></span></div><div></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><b><i>Explanation</i></b>:  Even though the DCs for hiatal hernia (7346) and IBS (7319) each fall within the range of DCs that the regulation says will not be separately evaluated and combined, they fall within the exception discussed in <a href=\"#1b\" target=\"_self\">M21-1, Part V, Subpart iii, 6.1.b</a> because effective May 19, 2024, <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=409c267ffb758e5b31de5f5cb2da025a&amp;mc=true&amp;node=se38.1.4_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.114, DC 7346</a> is evaluated using the criteria in <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=409c267ffb758e5b31de5f5cb2da025a&amp;mc=true&amp;node=se38.1.4_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.114, DC 7203</a> (stricture of the esophagus).  The 10-percent criteria for the two DCs do not overlap.  They do not compensate for the same disability or facet of disability, which is prohibited under <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-A/section-4.14\" target=\"_blank\">38 CFR 4.14</a>.  Note that under historical criteria, these DCs could not be separately evaluated and combined without pyramiding.  </span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">V.iii.6.1.e<a id=\"1e\" name=\"1e\">.</a>  Changes to the Rating Schedule for the Digestive System</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div class=\"MsoBlockText\"><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">The schedule of ratings – digestive system, <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=409c267ffb758e5b31de5f5cb2da025a&amp;mc=true&amp;node=se38.1.4_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.114</a>, was amended effective May 19, 2024.  The final rule added and deleted DCs, and extensively changed diagnostic criteria.  The final rule also deleted regulations with obsolete or redundant guidance on ulcers (<a href=\"https://www.ecfr.gov/compare/2024-03-20/to/2024-03-19/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR52ba1b312b58845/section-4.110\" target=\"_blank\">38 CFR 4.110</a>) and post-gastrectomy syndrome (<a href=\"https://www.ecfr.gov/compare/2024-03-20/to/2024-03-19/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR52ba1b312b58845/section-4.111\" target=\"_blank\">38 CFR 4.111</a>).  </span></span></div><div class=\"MsoBlockText\"></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">The purpose of the digestive system updates was to ensure that the rating schedule uses current medical terminology and to provide updated more objective evaluation criteria.  The changes were<b><i> not</i></b> intended as a liberalization.</span></span></div><div></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">When evaluating a claim involving evaluation of a digestive disability that was pending on May 19, 2024, apply the guidance in <a articleid=\"554400000180492\" articlename=\"M21-1, Part V, Subpart ii, Chapter 4, Section A - Effective Dates\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180492/M21-1-Part-V-Subpart-ii-Chapter-4-Section-A-Effective-Dates\">M21-1, Part V, Subpart ii, 4.A.6.p</a> on applicability of revised rating schedule criteria.</span></span></div><div></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><b><i>Important</i></b>:  In some instances, a digestive disorder may have been evaluated under analogous DC – whether using formal conventions for rating by analogy or not.  For example, prior to the current changes, gastroesophageal reflux disease (GERD) did not have its own DC.  The recommended DC for GERD in the past was 7346 (hiatal hernia).  It might appear on the <i>Codesheet</i> as “7399-7346” or just “7346.”  Now the DC is 7206. </span></span></div><div></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">Where a condition was previously rated by analogy but now has a specific DC, update the DC, but when considering the appropriate current evaluation, apply <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=b395daab3d4727abd2b162336385f1c8&amp;mc=true&amp;node=se38.1.3_1951&amp;rgn=div8\" target=\"_blank\">38 CFR 3.951(a)</a>.  Do <b><i>not</i></b> reduce the evaluation solely based on the changed criteria.  The evaluation can only be reduced when medical evidence establishes that the disability has actually improved.  Note that in the case of hiatal hernia and GERD, although the latter condition has its own DC the criteria for evaluating the two conditions is the same.  Hiatal hernia is rated as stricture of the esophagus (<a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=409c267ffb758e5b31de5f5cb2da025a&amp;mc=true&amp;node=se38.1.4_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.114, DC 7203</a>), which uses identical criteria to those in <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=409c267ffb758e5b31de5f5cb2da025a&amp;mc=true&amp;node=se38.1.4_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.114, DC 7206</a>.</span></span></div><div></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><b><i>Reference</i></b>:  For more information on protection and rating schedule changes, and reviewing evaluations after a rating schedule change, see <a articleid=\"554400000177962\" articlename=\"M21-1, Part X, Subpart ii, Chapter 1, Section B - Protected Ratings\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177962/M21-1-Part-X-Subpart-ii-Chapter-1-Section-B-Protected-Ratings\">M21-1, Part X, Subpart ii, 1.B.4</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><div class=\"ng-scope\" style=\"margin-left: 1.2in\"></div><p class=\"ng-scope\"> <br/> </p><h2 class=\"ng-scope\"><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">2<a id=\"2\" name=\"2\">.</a>  SC Considerations Involving Digestive Disabilities</span></span></h2><p class=\"ng-scope\"> <br/> </p><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">This topic contains information about SC considerations involving digestive disabilities, including</span></span></div><ul><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><a href=\"#2a\" target=\"_self\"><span style=\"font-size: 14px\">considering circumstances of service when determining SC for gastrointestinal disorders</span></a></span></div></li><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\"><a href=\"#2b\" target=\"_self\">testing not required for SC for GERD</a></span></span></div></li><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><a href=\"#2c\" target=\"_self\"><span style=\"font-size: 14px\">establishing SC for inguinal hernia</span></a></span></div></li><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><a href=\"#2d\" target=\"_self\"><span style=\"font-size: 14px\">SC and recurrence of hemorrhoids</span></a></span></div></li><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><a href=\"#2e\" target=\"_self\"><span style=\"font-size: 14px\">example of analyzing recurrence of hemorrhoids</span></a></span></div></li><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><a href=\"#2f\" target=\"_self\"><span style=\"font-size: 14px\">other causes of liver damage</span></a><span style=\"font-size: 14px\">, and</span></span></div></li><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><a href=\"#2g\" target=\"_self\"><span style=\"font-size: 14px\">fatty liver</span></a><span style=\"font-size: 14px\">.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">October 17, 2024</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.6.2.a<a id=\"2a\" name=\"2a\">.</a>  Considering Circumstances of Service When Determining SC for Gastrointestinal Disorders </span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">If the issue is service connection (SC) for dysentery or other gastrointestinal disease, assign great weight to any service under the following conditions since these conditions may have been the etiological or aggravating factor:</span></span></div><ul><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">tropical service</span></span></div></li><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">imprisonment or internment under unsanitary conditions, or</span></span></div></li><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">food deprivation.</span></span></div></li></ul><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\"><strong><em>Reference</em></strong>:  For more information on establishing presumptive SC for dysentery and other tropical diseases, see <a href=\"http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=1&amp;SID=7c54c98c7be24cd2f7b05eabb45f8a87&amp;ty=HTML&amp;h=L&amp;r=SECTION&amp;n=se38.1.3_1309\" target=\"_blank\">38 CFR 3.309(b)</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">V.iii.6.2.b<a id=\"2b\" name=\"2b\">.</a>  </span></span><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">Testing Not Required for SC for GERD</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">A diagnosis of GERD for SC purposes does not require documentation by medical imaging. </span></span></div><div></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFRef3d6710e800bcd/section-4.114\" target=\"_blank\">38 CFR 4.114, DC 7206, Note (1)</a> requires “findings” to be documented by one of three types of imaging:  barium swallow, computed tomography (CT), or esophagogastroduodenoscopy.  This refers to documentation of esophageal stricture for evaluation purposes.  It does not define a sufficient diagnosis of GERD for SC purposes. </span></span></div><div></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><b><i>Note</i></b>:  A 10-percent evaluation for GERD can also be assigned pursuant to <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-A/section-4.7\" target=\"_blank\">38 CFR 4.7</a> without imaging to document esophageal stricture when the Veteran requires daily medications.    </span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.6.2.c<a id=\"2c\" name=\"2c\">.</a>  Establishing SC for Inguinal Hernia</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">Do not assume the preexistence of a hernia.  Determine preexistence on a factual basis. </span></span></div><div></div><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">The following conditions are sufficient bases for SC:</span></span></div><ul><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">in-service initial manifestation of hernial protrusion, and</span></span></div></li><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">recurrence during service, by aggravation, of a hernia previously surgically repaired.</span></span></div></li></ul><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\"><strong><em>Note</em></strong>:  Operation for repair of a preexisting inguinal hernia is not necessarily evidence of aggravation.</span></span></div><div></div><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\"><strong><em>Reference</em></strong>:  For information on the presumption of soundness at entrance into service, see <a href=\"http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=1&amp;SID=7c54c98c7be24cd2f7b05eabb45f8a87&amp;ty=HTML&amp;h=L&amp;r=SECTION&amp;n=se38.1.3_1304\" target=\"_blank\">38 CFR 3.304(b)</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.6.2.d<a id=\"2d\" name=\"2d\">.</a>  SC and Recurrence of Hemorrhoids</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">Initial awards of SC for hemorrhoids are governed by customary rules for SC included in <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=f4e5818587afc2385dc0a750e18eb7f4&amp;mc=true&amp;node=se38.1.3_1303&amp;rgn=div8\" target=\"_blank\">38 CFR 3.303</a>.  </span></span></div><div></div><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">After SC is initially established, unless the award of SC for hemorrhoids was in error, consider recurrences after a period of absence of hemorrhoids post-service to be associated with the SC condition rather than a nonservice-connected superseding condition.</span></span></div><div></div><div><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\"><strong><em>Reference</em></strong>:  For more information on reversing an erroneous decision, see</span></span></div><ul><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\"><a href=\"http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=1&amp;SID=7c54c98c7be24cd2f7b05eabb45f8a87&amp;ty=HTML&amp;h=L&amp;r=SECTION&amp;n=se38.1.3_1105\" target=\"_blank\">38 CFR 3.105(a)</a>, and</span></span></div></li><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\"><a articleid=\"554400000177971\" articlename=\"M21-1, Part X, Subpart ii, Chapter 5, Section A - Revision Due to Clear and Unmistakable Error (CUE)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177971/M21-1-Part-X-Subpart-ii-Chapter-5-Section-A-Revision-Due-to-Clear-and-Unmistakable-Error-CUE\">M21-1, Part X, Subpart ii, 5.A</a></span><span style=\"font-size: 14px\">.</span></span></div></li></ul></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.6.2.e<a id=\"2e\" name=\"2e\">.</a>  Example: Analyzing Recurrence of Hemorrhoids</span></span></h3><h3></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><strong><em>Situation</em></strong>:  SC is established for hemorrhoids first diagnosed during service. A 0-percent evaluation was assigned under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=99923fa4aa6e88e29512e11f1e18ec97&amp;mc=true&amp;node=se38.1.4_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.114, DC 7336</a>. </span></span></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"> </span></span></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">Two years after SC was granted for hemorrhoids, the Veteran filed a claim for increased evaluation.  Examination showed no hemorrhoids.  The diagnosis was “hemorrhoids, not shown.”  The 0-percent evaluation was continued. </span></span></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"> </span></span></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">Five years later the Veteran filed a claim for an increased evaluation for hemorrhoids.  Records showed three instances of doctor visits in the last year for external hemorrhoids with thrombosis.  The Veteran reported a history of “old” problems with hemorrhoids and recent symptoms including bright red blood noted with defecation and discomfort with protracted sitting in his current job.  A Department of Veterans Affairs examination included a similar history and showed external hemorrhoids with thrombosis.  The diagnosis was “external hemorrhoids.”  Examination findings and findings in treatment records demonstrate the criteria for 10-percent evaluation in <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=99923fa4aa6e88e29512e11f1e18ec97&amp;mc=true&amp;node=se38.1.4_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.114, DC 7336</a>. </span></span></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"> </span></span></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><b><i>Result</i></b>:  Assign a 10-percent evaluation.  The facts suggest that the SC hemorrhoids were non-disabling, or even absent, for an indeterminate period after SC was granted, and the Veteran’s current history in medical records and at the VA examination could suggest that the current hemorrhoids are due to a superseding post-service cause (protracted sitting at work).  However, the evidence does not prove that current hemorrhoids are due to a superseding cause or that SC was in error.  Pursuant to the principle in <a href=\"#2d\" target=\"_self\">M21-1, Part V, Subpart iii, 6.2.d</a>, after SC is initially established, consider hemorrhoids shown after a period of absence to be associated with the SC condition rather than due to a superseding post service cause unless the award of SC for hemorrhoids was clearly in error.  Do not return the examination for comment on that question.  </span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.6.2.f<a id=\"2f\" name=\"2f\">.</a>  Other Causes of Liver Damage</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">The table below describes recognized causes of liver damage and provides examples of each cause.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">  </span></span><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width: 510px; border-spacing: 1px; border-collapse: revert;\" summary=\"Column 1 provides the cause of liver damage and column 2 provides an example of the cause.\" width=\"510\"><thead><tr><th scope=\"col\" style=\"width: 258px; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong>Cause of Liver Damage</strong></span></span></div></th><th scope=\"col\" style=\"width: 252px; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong>Example </strong></span></span></div></th></tr></thead><tbody><tr><td style=\"width: 258px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Infection</span></span></div></td><td style=\"width: 252px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Virus</span></span></div></td></tr><tr><td style=\"width: 258px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Systemic diseases</span></span></div></td><td style=\"width: 252px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Lupus</span></span></div></td></tr><tr><td style=\"width: 258px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Drugs</span></span></div></td><td style=\"width: 252px; padding: 1px;\"><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Isoniazid</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Acetaminophen</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Phenytoin</span></span></div></li></ul></td></tr><tr><td style=\"width: 258px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Toxic substances</span></span></div></td><td style=\"width: 252px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Alcohol</span></span></div></td></tr></tbody></table></div><div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.6.2.g<a id=\"2g\" name=\"2g\">.</a>  Fatty Liver</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Fatty liver, also called hepatic steatosis, is not a disability for which SC can be granted.  By itself it is simply considered an abnormal laboratory finding. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on abnormal laboratory findings discovered in STRs without a claim, see <a articleid=\"554400000180488\" articlename=\"M21-1, Part V, Subpart ii, Chapter 3, Section C - Reviewing Diagnoses\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180488/M21-1-Part-V-Subpart-ii-Chapter-3-Section-C-Reviewing-Diagnoses\">M21-1, Part V, Subpart ii, 3.C.1.d</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><div class=\"ng-scope\" style=\"margin-left: 85pt\"></div><h2 class=\"ng-scope\"><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">3<a id=\"3\" name=\"3\">.</a>  Hepatitis</span></span><br/><br/> </h2><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" spellcheck=\"false\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Introduction</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">This topic contains information about hepatitis, including </span></span></p><ul><li><a href=\"#3a\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">categories of hepatitis recognized for rating purposes</span></span></a></li><li><a href=\"#3b\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">diagnostic testing required for hepatitis</span></span></a></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">interpreting lab reports for </span></span><ul><li><a href=\"#3c\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">hepatitis B (HBV)</span></span></a>, and</li><li><a href=\"#3d\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">hepatitis C (HCV) after 1992</span></span></a></li></ul></li><li><a href=\"#3e\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">risk factors for HBV and HCV</span></span></a></li><li><a href=\"#3f\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">development for hepatitis risk factors</span></span></a></li><li><a href=\"#3g\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">considering drug abuse in hepatitis claims</span></span></a></li><li><a href=\"#3h\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">evaluating claims for increase for SC hepatitis awarded due to drug abuse</span></span></a></li><li><a href=\"#3i\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">considering in-service hepatitis findings</span></span></a></li><li><a href=\"#3j\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">requesting exams and/or opinions for HBV or HCV</span></span></a></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#3k\" target=\"_self\">reviewing hepatitis exams and opinions for sufficiency</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#3l\" target=\"_self\">assigning a 0-percent evaluation for HCV</a>.</span></span></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Change Date</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">April 21, 2025</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.6.3.a<a id=\"3a\" name=\"3a\">.</a> Categories of Hepatitis Recognized for Rating Purposes</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">There are three main categories of viral hepatitis recognized for rating purposes.  The table below describes each type of hepatitis and explains the transmission and prognosis for each.</span></span></div><div></div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width: 510px; border-spacing: 1px; border-collapse: revert;\" summary=\"Column 1 provides the type of hepatitis, column 2 provides the transmission, and column 3 provides the prgnosis.\" width=\"510\"><thead><tr><th scope=\"col\" style=\"width: 168px; padding: 1px;\"><p align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Type of Hepatitis</strong></span></span></p></th><th scope=\"col\" style=\"width: 138px; padding: 1px;\"><p align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Transmission</strong></span></span></p></th><th scope=\"col\" style=\"width: 204px; padding: 1px;\"><p align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Prognosis</strong></span></span></p></th></tr></thead><tbody><tr><td style=\"width: 168px; vertical-align: top; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">hepatitis A virus (HAV), previously called infectious hepatitis</span></span></p></td><td style=\"width: 138px; vertical-align: top; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">fecal-oral route</span></span></p></td><td style=\"width: 204px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Acute—seldom severe and does not leave residuals.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Note</em></strong>:  In order to award SC, there must be evidence of chronic residuals related to the hepatitis A infection. </span></span></div></td></tr><tr><td style=\"width: 168px; vertical-align: top; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">hepatitis B virus (HBV), previously called serum hepatitis</span></span></p></td><td style=\"width: 138px; vertical-align: top; padding: 1px;\"><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">blood products</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">sexual contact</span></span></li></ul></td><td style=\"width: 204px; padding: 1px;\"><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Acute in 90-95 percent of cases, but acute disease can be severe and result in death.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Chronic in 5-10 percent of cases.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Cirrhosis and liver cancer may develop.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">A vaccine to prevent HBV infection is available.</span></span></li></ul></td></tr><tr><td style=\"width: 168px; vertical-align: top; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">hepatitis C virus (HCV), previously called non-A non-B hepatitis</span></span></p></td><td style=\"width: 138px; vertical-align: top; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">infected blood</span></span></p></td><td style=\"width: 204px; padding: 1px;\"><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Clinically asymptomatic acute disease.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Chronic disease develops in 80 percent of cases following acute phase.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Diagnosis is generally made incidentally many years later.</span></span></li></ul></td></tr></tbody></table><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Note</em></strong>:  Infectious hepatitis is common throughout the world and was especially prevalent during World War II following administration of the yellow fever vaccine in 1942 and in the Mediterranean Theater.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Reference</em></strong>:  For more information on risk factors for HBV and HCV, see <a href=\"#3e\" target=\"_self\">M21-1, Part V, Subpart iii, 6.3.e</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.6.3.b<a id=\"3b\" name=\"3b\">.</a> Diagnostic Testing Required for Hepatitis</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">SC for hepatitis requires blood serology testing to establish a diagnosis and identify the type of hepatitis present.  Liver function tests (LFTs) are necessary to assess the severity of the disease.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Notes</em></strong>:</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The rating decision should always specify the type of hepatitis for which SC is awarded.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><em>Serological tests</em> determine the presence of antigens and antibodies to the specific virus.  The presence of antibodies to the specific virus indicates the infection is present. </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The table below describes types of serological testing required to confirm a diagnosis for each type of hepatitis.</span></span></div><div></div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width: 510px; border-spacing: 1px; border-collapse: revert;\" summary=\"Column 1 provides the type of hepatitis, column 2 provides the serology or other testing required, and column 3 provides additional notes.\" width=\"510\"><thead><tr><th scope=\"col\" style=\"width: 138px; padding: 1px;\"><p align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Type of Hepatitis</strong></span></span></p></th><th scope=\"col\" style=\"width: 186px; padding: 1px;\"><p align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Serology or Other Testing Required</strong></span></span></p></th><th scope=\"col\" style=\"width: 186px; padding: 1px;\"><p align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Additional Notes</strong></span></span></p></th></tr></thead><tbody><tr><td style=\"width: 138px; vertical-align: top; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">HAV</span></span></p></td><td style=\"width: 186px; vertical-align: top; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">anti-HAV (antibodies to hepatitis A virus)</span></span></p></td><td style=\"width: 186px; padding: 1px;\"><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Anti-HAV are present in the blood one month after the acute illness and persist for life.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Serological blood testing showing the presence of anti-HAV indicates a past acute infection.</span></span></li></ul></td></tr><tr><td style=\"width: 138px; vertical-align: top; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">HBV</span></span></p></td><td style=\"width: 186px; vertical-align: top; padding: 1px;\"><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">anti-HBsAg (hepatitis B surface antigen) is present during the acute phase.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">HBsAg that persists more than three to six months indicates probable chronic disease or carrier status.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">A positive Australian antigen test is sufficient to confirm HBV.</span></span></li></ul><p style=\"margin-left: 7.9pt\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></p></td><td style=\"width: 186px; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">HBV has two antigens, a surface antigen and a core antigen</span></span></p><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">HBsAg, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">HBcAg (hepatitis B core antigen).</span></span></li></ul><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Consequently, two types of antibodies appear in the blood</span></span></p><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">anti-HBs (antibodies to the surface antigen), and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">anti-HBc (antibodies to the core antigen).</span></span></li></ul></td></tr><tr><td style=\"width: 138px; vertical-align: top; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">HCV</span></span></p></td><td style=\"width: 186px; padding: 1px;\"><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">EIA (enzyme immunoassay) or ELISA (enzyme linked immunosorbent assay, also called Western blot) is the first test.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">If EIA or ELISA is positive, RIBA (recombinant immunoblot assay) is needed to confirm the diagnosis of chronic HCV.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">In lieu of EIA/ELISA followed by RIBA, a positive test for HCV RNA (hepatitis C viral ribonucleic acid) is sufficient by itself to confirm a diagnosis of HCV.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">HCV RNA results can be</span></span><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">qualitative (positive or negative), or</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">quantitative (number of copies per milliliter (ml)).</span></span></li></ul></li></ul></td><td style=\"width: 186px; vertical-align: top; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The presence of anti-HCV (including EIA or ELISA) is <strong><em>not</em></strong> sufficient for a diagnosis of chronic HCV because it can be present in other diseases.</span></span></p></td></tr></tbody></table><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Note</em></strong>:  Liver biopsy, ultrasound, and CT scan tests can detect damage to the liver but will not identify the type of infection.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.6.3.c<a id=\"3c\" name=\"3c\">.</a> Interpreting Lab Reports for HBV</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The table below provides an example of a laboratory interpretation of serology test results for HBV.</span></span></div><div></div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"border-spacing: 1px; border-collapse: revert;\" summary=\"This is an example of a lboratory interpretation of seology test results for HBV.  Column 1 provides the test, column 1 provides the results, andcolumn 3 provides the interpretation.\" width=\"507\"><thead><tr><th scope=\"col\" style=\"width: 158px; padding: 1px;\"><p style=\"text-align: center\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong><u>Test</u></strong></span></span></p></th><th scope=\"col\" style=\"width: 156px; padding: 1px;\"><p style=\"text-align: center\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong><u>Results</u></strong></span></span></p></th><th scope=\"col\" style=\"width: 192px; padding: 1px;\"><p style=\"text-align: center\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong><u>Interpretation</u></strong></span></span></p></th></tr></thead><tbody><tr><td colspan=\"3\" style=\"width: 507px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><u><strong>Example 1</strong></u></span></span></p></td></tr><tr><td style=\"width: 158px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><u>HBsAg</u></span></span></p></td><td style=\"width: 156px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">negative</span></span></p></td><td style=\"width: 192px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">susceptible to infection</span></span></p></td></tr><tr><td style=\"width: 158px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><u>anti-HBc</u></span></span></p></td><td style=\"width: 156px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">negative</span></span></p></td><td style=\"width: 192px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">susceptible to infection (no HBV)</span></span></p></td></tr><tr><td style=\"width: 158px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">anti-HBs</span></span></p></td><td style=\"width: 156px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">negative</span></span></p></td><td style=\"width: 192px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">no history of HBV</span></span></p></td></tr><tr><td colspan=\"3\" style=\"width: 507px; padding: 1px;\"></td></tr><tr><td colspan=\"3\" style=\"width: 507px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong><u>Example 2</u></strong></span></span></p></td></tr><tr><td style=\"width: 158px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">HBsAg</span></span></p></td><td style=\"width: 156px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">negative</span></span></p></td><td style=\"width: 192px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">immune</span></span></p></td></tr><tr><td style=\"width: 158px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">anti-HBc</span></span></p></td><td style=\"width: 156px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">negative or positive</span></span></p></td><td style=\"width: 192px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">immune</span></span></p></td></tr><tr><td style=\"width: 158px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">anti-HBs</span></span></p></td><td style=\"width: 156px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">positive</span></span></p></td><td style=\"width: 192px; padding: 1px;\"></td></tr><tr><td colspan=\"3\" style=\"width: 507px; padding: 1px;\"></td></tr><tr><td colspan=\"3\" style=\"width: 507px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong><u>Example 3</u></strong></span></span></p></td></tr><tr><td style=\"width: 158px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">HBsAg</span></span></p></td><td style=\"width: 156px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">positive</span></span></p></td><td style=\"width: 192px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">acute infection</span></span></p></td></tr><tr><td style=\"width: 158px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">anti-HBc</span></span></p></td><td style=\"width: 156px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">positive</span></span></p></td><td style=\"width: 192px; padding: 1px;\"></td></tr><tr><td style=\"width: 158px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">Immunoglobulin M (IgM) anti-HBc</span></span></p></td><td style=\"width: 156px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">positive</span></span></p></td><td style=\"width: 192px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">acute infection</span></span></p></td></tr><tr><td style=\"width: 158px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">anti-HBs</span></span></p></td><td style=\"width: 156px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">negative</span></span></p></td><td style=\"width: 192px; padding: 1px;\"></td></tr><tr><td colspan=\"3\" style=\"width: 507px; padding: 1px;\"></td></tr><tr><td colspan=\"3\" style=\"width: 507px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong><u>Example 4</u></strong></span></span></p></td></tr><tr><td style=\"width: 158px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">HBsAg</span></span></p></td><td style=\"width: 156px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">positive</span></span></p></td><td style=\"width: 192px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">chronic infection</span></span></p></td></tr><tr><td style=\"width: 158px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">anti-HBc</span></span></p></td><td style=\"width: 156px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">positive</span></span></p></td><td style=\"width: 192px; padding: 1px;\"></td></tr><tr><td style=\"width: 158px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">IgM anti-HBc</span></span></p></td><td style=\"width: 156px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">negative</span></span></p></td><td style=\"width: 192px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">chronic infection</span></span></p></td></tr><tr><td style=\"width: 158px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">anti-HBs</span></span></p></td><td style=\"width: 156px; padding: 1px;\"><p><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">negative</span></span></p></td><td style=\"width: 192px; padding: 1px;\"></td></tr></tbody></table><div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.6.3.d<a id=\"3d\" name=\"3d\">.</a> Interpreting Lab Reports for HCV After 1992</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The table below provides an example of a laboratory interpretation of serology testing for HCV for testing performed after 1992.</span></span></div><div></div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"border-spacing: 1px; border-collapse: revert;\" summary=\"This table is an example of a laboratory interpretation of serology testing for HCV for testing performed after 1992.  Column 1 provides the test, column 1 provides the results, andcolumn 3 provides the interpretation.\" width=\"507\"><thead><tr><th scope=\"col\" style=\"width: 158px; padding: 1px;\"><p style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><u>Tests </u></strong></span></span></p></th><th scope=\"col\" style=\"width: 156px; padding: 1px;\"><p style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><u>Results</u></strong></span></span></p></th><th scope=\"col\" style=\"width: 192px; padding: 1px;\"><p style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><u>Interpretation</u></strong></span></span></p></th></tr></thead><tbody><tr><td style=\"width: 158px; vertical-align: top; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">anti-HCV</span></span></p></td><td style=\"width: 156px; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">positive (probable chronic hepatitis)</span></span></p></td><td style=\"width: 192px; vertical-align: top; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">need to verify diagnosis</span></span></p></td></tr><tr><td style=\"width: 158px; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">EIA</span></span></p></td><td style=\"width: 156px; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">positive</span></span></p></td><td style=\"width: 192px; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">supplemental test required</span></span></p></td></tr><tr><td style=\"width: 158px; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">RIBA</span></span></p></td><td style=\"width: 156px; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">positive</span></span></p></td><td style=\"width: 192px; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">diagnostic</span></span></p></td></tr><tr><td style=\"width: 158px; vertical-align: top; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">HCVRNA</span></span></p></td><td style=\"width: 156px; vertical-align: top; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">follow-up of chronic HCV</span></span></p></td><td style=\"width: 192px; vertical-align: top; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">not needed for rating</span></span></p></td></tr></tbody></table><div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.6.3.e<a id=\"3e\" name=\"3e\">.</a>  Risk Factors for HBV and HCV</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Risk factors for the development of HBV and HCV are similar.  The table below describes the medically recognized risk factors for HBV and HCV infection, provides transmission information concerning those risk factors, and includes tips for confirming the risk factors.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Note</em></strong>:  Resolve reasonable doubt under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=11a8c42004846650332ce6e28ab91057&amp;mc=true&amp;node=se38.1.3_1102&amp;rgn=div8\" target=\"_blank\">38 CFR 3.102</a> in favor of the Veteran when the evidence favoring risk factor(s) in service is equal to the evidence favoring risk factor(s) before or after service.</span></span></div><div></div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width: 510px; border-spacing: 1px; border-collapse: revert;\" summary=\"Column 1 provides the risk factor, column 2 provides the transmisstion information, and column 3 provides rating tips.\" width=\"510\"><thead><tr><th scope=\"col\" style=\"width: 174px; padding: 1px;\"><p align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Risk Factor</strong></span></span></p></th><th scope=\"col\" style=\"width: 162px; padding: 1px;\"><p align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Transmission Information </strong></span></span></p></th><th scope=\"col\" style=\"width: 174px; padding: 1px;\"><p align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Rating Tips</strong></span></span></p></th></tr></thead><tbody><tr><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">transfusion of blood or blood product</span></span><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">before 1992 for HCV, or</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">before 1975 for HBV</span></span></li></ul></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">organ transplant before 1992, or</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">hemodialysis</span></span></li></ul></td><td style=\"width: 162px; vertical-align: top; padding: 1px;\"><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Blood donor screening for HCV was not available until 1989 when HCV was identified.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">In 1992, more effective screening of blood became possible for HCV.</span></span></li></ul></td><td style=\"width: 174px; padding: 1px;\"><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">If blood transfusion is a claimed risk factor, obtain the relevant hospital records from service, if possible.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Look for evidence of blood transfusions in surgical reports, especially the</span></span><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">anesthesia sheet</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">surgical record</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">operative clinical records, or</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">post-operative clinical notes.</span></span></li></ul></li></ul></td></tr><tr><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">tattoos</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">body piercing, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">acupuncture with non-sterile needles</span></span></li></ul></td><td style=\"width: 162px; vertical-align: top; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">transmitted through the use of unsterilized equipment</span></span></p></td><td style=\"width: 174px; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Review for indications of tattoos or piercings on induction and separation exams to help determine whether tattooing or piercing took place in service.</span></span></p></td></tr><tr><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">intravenous drug use</span></span></p></td><td style=\"width: 162px; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">transmitted through the use of shared instruments</span></span></p></td><td style=\"width: 174px; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Records of drug treatment may reflect the type of drug abuse.</span></span></p></td></tr><tr><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">high-risk sexual activity</span></span></p></td><td style=\"width: 162px; vertical-align: top; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Transmission risk is relatively low but increases with multiple sexual partners.</span></span></p></td><td style=\"width: 174px; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Periodic health assessments or records of treatment for sexually transmitted diseases may document a history of high-risk sexual activity or multiple sexual partners.</span></span></p></td></tr><tr><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">intranasal cocaine use</span></span></p></td><td style=\"width: 162px; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">transmitted through the use of shared instruments</span></span></p></td><td style=\"width: 174px; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Records of drug treatment may reflect the type of drug abuse.</span></span></p></td></tr><tr><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">accidental exposure to blood by percutaneous exposure or on mucous membranes</span></span></p></td><td style=\"width: 162px; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">common for the following:</span></span></p><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">health care workers</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">combat medics, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">corpsmen</span></span></li></ul></td><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Consider service department or other records reflecting occupational history.</span></span></p></td></tr><tr><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">sharing of</span></span></p><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">toothbrushes, or</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">shaving razors</span></span></li></ul></td><td style=\"width: 162px; vertical-align: top; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">transmitted through direct percutaneous exposure to blood</span></span></p></td><td style=\"width: 174px; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">This type of in-service exposure will not generally be documented in service records. Consider buddy statements in the context of the entire evidence picture pertaining to risk factors.</span></span></p></td></tr><tr><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">immunization with a jet air gun injector</span></span></p></td><td style=\"width: 162px; padding: 1px;\"><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><em>one</em> documented case of HBV transmission</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Despite the lack of any scientific evidence to document transmission of HCV with air gun injectors, it is biologically possible.</span></span></li></ul></td><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">A medical report linking hepatitis to air gun injectors must include a full discussion of all potential modes of transmission and a rationale as to why the examiner believes the air gun injector was the source for the hepatitis infection.</span></span></p></td></tr></tbody></table><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em><strong>Reference</strong></em>:  For more information on development for and the concession of in-service risk factors associated with HCV, see <a articleid=\"554400000195463\" articlename=\"Andrews v. McDonough, June 22, 2021, 34 Vet.App. 216\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000195463/Andrews-v-McDonough-June-22-2021-34-VetApp-216\"><em>Andrews v. McDonough</em></a>, 34 Vet.App. 151 (2021).</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.6.3.f<a id=\"3f\" name=\"3f\">.</a> Development for Hepatitis Risk Factors</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">As <a href=\"http://www.vba.va.gov/pubs/forms/VBA-21-526EZ-ARE.pdf\" target=\"_blank\"><em>VA Form 21-526EZ, Application for Disability Compensation and Related Compensation Benefits</em></a>, does not inform the claimant to submit evidence of hepatitis risk factors, development for risk factors is required in every hepatitis claim, even when hepatitis is diagnosed in service.  Development is necessary to determine if pre- and post-service risk factors are present as well as to ensure that the risk factor is not substance abuse either before or during service.</span></span></div><div></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">Regardless of what claim form the Veteran submits, development for risk factors is required if the complete risk factor history has not already been provided.  If risk factor history is not of record send a risk factor development letter to the Veteran.</span></span></div><div></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><em><strong>References</strong></em>:  For more information on</span></span></div><ul><li><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">SC for hepatitis associated with drug use, see <a href=\"#3g\" target=\"_self\">M21-1, Part V, Subpart iii, 6.3.g</a>, and</span></span></div></li><li><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">examinations and medical opinions in hepatitis claims, see <a href=\"#3j\" target=\"_self\">M21-1, Part V, Subpart iii, 6.3.j</a>.  </span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.6.3.g<a id=\"3g\" name=\"3g\">.</a> Considering Drug Abuse in Hepatitis Claims</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">If one of the risk factors for hepatitis is intravenous or intramuscular drug use, or intranasal cocaine use, do <strong><em>not</em></strong> automatically assume the substance abuse is the cause of hepatitis and deny the claim on that basis. </span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Follow the steps in the table below when considering a claim for SC for hepatitis in which injection drug or intranasal cocaine use is a confirmed in-service risk factor. </span></span></div><div></div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width: 510px; border-spacing: 1px; border-collapse: revert;\" summary=\"This is a step-action table.  Column 1 is the step number and column 2 provides the actions to take when considering a claim for SC for hepatitis in which injection drug or intranasal cocaine use is a confirmed in-service risk factor.   Stpe 4 contains and additional table.\" width=\"510\"><thead><tr><th scope=\"col\" style=\"width: 72px; padding: 1px;\"><p align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Step</strong></span></span></p></th><th scope=\"col\" style=\"width: 438px; padding: 1px;\"><p align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Action</strong></span></span></p></th></tr></thead><tbody><tr><td style=\"width: 72px; padding: 1px;\"><p align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">1</span></span></p></td><td style=\"width: 438px; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Review for all risk factors of hepatitis in addition to the drug use.</span></span></p></td></tr><tr><td style=\"width: 72px; padding: 1px;\"><p align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">2</span></span></p></td><td style=\"width: 438px; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">If injection drug or intranasal cocaine use is the only confirmed in-service risk factor present, then deny SC. If other in-service risk factors are found in addition to injection drug or intranasal cocaine use, go to Step 3.</span></span></p></td></tr><tr><td style=\"width: 72px; padding: 1px;\"><p align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">3</span></span></p></td><td style=\"width: 438px; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Request a medical opinion to determine which confirmed in-service risk factor is at least as likely as not the cause of the hepatitis infection.</span></span></p></td></tr><tr><td style=\"width: 72px; padding: 1px;\"><p align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">4</span></span></p></td><td style=\"width: 438px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Use the table below to determine how to proceed with the medical opinion.</span></span></div><div></div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"border-spacing: 1px; border-collapse: revert;\" summary=\"This is an if-then table.  Column 1 provides the criteria and column 2 provides the action to take.\"><thead><tr><th scope=\"col\" style=\"width: 196px; padding: 1px;\"><p style=\"text-align: left\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong>If the medical opinion …</strong></span></span></p></th><th scope=\"col\" style=\"width: 226px; padding: 1px;\"><p style=\"text-align: left\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><strong>Then …</strong></span></span></p></th></tr></thead><tbody><tr><td style=\"width: 196px; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">states that drug use is the cause of the hepatitis infection</span></span></p></td><td style=\"width: 226px; vertical-align: top; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">deny the claim for SC for hepatitis.</span></span></p></td></tr><tr><td style=\"width: 196px; vertical-align: top; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">gives greater or equal weight to another confirmed in-service risk factor</span></span></p></td><td style=\"width: 226px; padding: 1px;\"><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">resolve reasonable doubt in the Veteran’s favor, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">award SC.</span></span></li></ul></td></tr><tr><td style=\"width: 196px; vertical-align: top; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">is unable to state which risk factor is more likely than not to be the cause of the hepatitis</span></span></p></td><td style=\"width: 226px; padding: 1px;\"><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">weigh all evidence, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">apply the reasonable doubt doctrine if the evidence is found to be in equipoise.</span></span></li></ul><p><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on examiner statements that an opinion would be speculative, see <a articleid=\"554400000180514\" articlename=\"M21-1, Part IV, Subpart i, Chapter 3, Section A - General Criteria for Sufficiency of Examination Reports\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180514/M21-1-Part-IV-Subpart-i-Chapter-3-Section-A-General-Criteria-for-Sufficiency-of-Examination-Reports\">M21-1, Part IV, Subpart i, 3.A.1.q</a>.</span></span></p></td></tr></tbody></table><div></div></td></tr></tbody></table><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Reference</em></strong>:  For more information on considering claims for SC based on drug use, see</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=290d6d4d738a59a099fe3225e78f6388&amp;node=se38.1.3_1301&amp;rgn=div8\" target=\"_blank\">38 CFR 3.301(c)(3)</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a articleid=\"554400000177988\" articlename=\"M21-1, Part X, Subpart iv, Chapter 1, Section D  - Disability  or Death from Use of Alcohol, Drugs, or Tobacco Products\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177988/M21-1-Part-X-Subpart-iv-Chapter-1-Section-D-Disability-or-Death-from-Use-of-Alcohol-Drugs-or-Tobacco-Products\">M21-1, Part X, Subpart iv, 1.D.2</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.6.3.h<a id=\"3h\" name=\"3h\">.</a>﻿  Evaluating Claims for Increase for SC Hepatitis Awarded Due to Drug Abuse</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Follow the steps in the table below to determine the appropriate actions to take in a claim for increase when SC was previously awarded but the only apparent risk factor in service was drug abuse.</span></span></div><div></div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width: 510px; border-spacing: 1px; border-collapse: revert;\" summary=\"This is a step-action table.  Column 1 is the step number and column 2 provides information to determine the appropriate actions to take in a claim for increase when SC was previously awarded but the only apparent risk factor in service was drug abuse.\" width=\"510\"><thead><tr><th scope=\"col\" style=\"width: 72px; padding: 1px;\"><p align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Step</strong></span></span></p></th><th scope=\"col\" style=\"width: 438px; padding: 1px;\"><p align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Action</strong></span></span></p></th></tr></thead><tbody><tr><td style=\"width: 72px; vertical-align: top; padding: 1px;\"><p align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>1</strong></span></span></p></td><td style=\"width: 438px; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Was SC for hepatitis due to drug abuse awarded by rating decision on or before October 31, 1990?</span></span></p><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">If <em>yes</em>, then continue the finding of SC for hepatitis as the award of SC was proper based on regulations and procedures at that time. Go to Step 5.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">If <em>no</em>, then go to Step 2.</span></span></li></ul></td></tr><tr><td style=\"width: 72px; vertical-align: top; padding: 1px;\"><p align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">2</span></span></p></td><td style=\"width: 438px; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Does the evidence clearly show that the hepatitis is due to in-service drug abuse?</span></span></p><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">If <em>yes</em>, go to Step 4.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">If <em>no</em>, go to Step 3.</span></span></li></ul></td></tr><tr><td style=\"width: 72px; vertical-align: top; padding: 1px;\"><p align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">3</span></span></p></td><td style=\"width: 438px; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">If SC was awarded but there is no evidence clearly linking the hepatitis to drug abuse or if there were multiple risk factors in service, one of which was drug abuse, and no prior opinion was obtained, request a medical opinion to determine whether the hepatitis is due to the drug abuse.</span></span></p><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">If the resulting opinion</span></span></p><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">clearly links hepatitis to drug abuse, go to Step 4.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">cannot resolve whether hepatitis is due to drug abuse or another in-service risk factor, or the hepatitis is attributed to another non-drug abuse in-service risk factor, then</span></span><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">resolve reasonable doubt in favor of the Veteran and continue the finding of SC, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">award an increased evaluation for hepatitis if the medical evidence otherwise shows the increase is warranted.</span></span></li></ul></li></ul></td></tr><tr><td style=\"width: 72px; vertical-align: top; padding: 1px;\"><p align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">4</span></span></p></td><td style=\"width: 438px; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">If the evidence clearly shows that the hepatitis is due to in-service drug abuse and SC was awarded by rating decision after October 31, 1990, determine whether the award of SC is protected per <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=eb7e5f1a68f287026d33281f48329284&amp;node=se38.1.3_1957&amp;rgn=div8\" target=\"_blank\">38 CFR 3.957</a>.</span></span></p><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">If SC. is protected, go to Step 5.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">If SC is not protected, then propose to sever SC per <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=642574e012687e22e2367579161048b5&amp;node=se38.1.3_1105&amp;rgn=div8\" target=\"_blank\">38 CFR 3.105(a)</a>.</span></span></li></ul></td></tr><tr><td style=\"width: 72px; vertical-align: top; padding: 1px;\"><p align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">5</span></span></p></td><td style=\"width: 438px; padding: 1px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">If SC was properly established for hepatitis due to drug abuse by rating decision on or before October 31, 1990, and/or if the award of SC for hepatitis is protected, do not award an increased evaluation for hepatitis due to drug abuse.</span></span></p></td></tr></tbody></table><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Notes</em></strong>:</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">The Omnibus Reconciliation Act of 1990 (<em>Public Law 101-508 Section 8052</em>) prohibited the grant of SC for disability or death resulting from alcohol or drug abuse for claims filed after October 31, 1990.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a articleid=\"554400000043738\" articlename=\"VAOPGCPREC 02-98, Feb 10, 1998, Benefits Based on Service Connected Disability or Death - Disabilities Resulting from Alcohol or Drug Abuse - Pub. L. No. 101-508, § 8052\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000043738/VAOPGCPREC-02-98-Feb-10-1998-Benefits-Based-on-Service-Connected-Disability-or-Death-Disabilities-Resulting-from-Alcohol-or-Drug-Abuse-Pub-L-No-101-508-8052\">VAOPGCPREC 2-1998</a> found that an increased evaluation may not be awarded when SC was previously properly established as due to drug abuse by rating decision on or before October 31, 1990.</span></span></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.6.3.i<a id=\"3i\" name=\"3i\">.</a><br/>Considering In-Service Hepatitis Findings</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">When a Veteran submits a claim for SC of hepatitis, assess the lay evidence, service treatment records (STRs), and current medical records to ascertain whether a current disability, an in-service event or injury, and an indication of an association are present as required in <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=1e324e06ebb226eb099aa96f320959d2&amp;node=se38.1.3_1159&amp;rgn=div8\" target=\"_blank\">38 CFR 3.159(c)(4)</a> prior to requesting examination and/or medical opinion. </span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Use the table below to determine the proper rating action for in-service findings related to hepatitis.</span></span></div><div></div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"border-spacing: 1px; border-collapse: revert;\" summary=\"This is an If-Then table.  Column 1 provides the criteria and column 2 provides information to determine the proper rating action for in-service findings related to hepatitis.\" width=\"507\"><thead><tr><th scope=\"col\" style=\"width: 40.74%; padding: 1px;\"><p style=\"text-align: left\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>If STRs show ...</strong></span></span></p></th><th scope=\"col\" style=\"width: 59.26%; padding: 1px;\"><p style=\"text-align: left\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Then ...</strong></span></span></p></th></tr></thead><tbody><tr><td style=\"width: 40%; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">diagnosis of non-specific hepatitis and SC is claimed many years later</span></span></div></td><td style=\"width: 59.26%; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">request an exam with serology testing and LFTs (if not already of record) and opinion to determine if a relationship exists between the episode of hepatitis in service and the current type of hepatitis unless there is sufficient evidence of a clearly-established diagnosis and continuous symptoms present to satisfy the nexus standard under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=7ba4ca19cef35152b0b6015d80b0df65&amp;node=se38.1.3_1303&amp;rgn=div8\" target=\"_blank\">38 CFR 3.303(b)</a>.</span></span></div></td></tr><tr><td style=\"width: 40%; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">laboratory findings confirming HAV or HBV</span></span></div></td><td style=\"width: 59.26%; padding: 1px;\"><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">SC for HAV is not warranted as HAV is an acute condition.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Consider SC for HBV if a chronic disability is present and linked to the in-service finding and/or risk factors.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Consider SC for HCV if a medical opinion links the condition to the confirmed in-service findings and/or risk factors.  However, do not automatically grant SC for HCV.  The lab findings in service alone do not show HCV in service or allow a conclusion that HCV was incurred in service.  Each type of hepatitis can be acquired at different times and through different means.   </span></span></li></ul></td></tr><tr><td style=\"width: 40%; vertical-align: top; padding: 1px;\"><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">a diagnosis of non-A, non-B hepatitis (old name for HCV) and the current medical evidence confirms a diagnosis of HCV</span></span></div></td><td style=\"width: 59%; vertical-align: top; padding: 1px;\"><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">SC is likely warranted.</span></span></div><ul><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">If medical evidence establishes the presence of continuous symptoms since service, then award SC.</span></span></div></li><li><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">If evidence of continuous symptoms since service is not present, request a nexus opinion.</span></span></div></li></ul></td></tr><tr><td style=\"width: 40%; vertical-align: top; padding: 1px;\"><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">non-specific hepatitis and current evidence shows HCV <strong>or </strong>chronic HBV only</span></span></div></td><td style=\"width: 59.26%; padding: 1px;\"><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">HCV or chronic HBV <em>may</em> warrant SC based on reasonable doubt. Request a medical opinion and any necessary diagnostic testing to confirm the diagnosis.</span></span></div><div></div><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\"><strong><em>Reference</em></strong>:  For more information on diagnostic testing required for hepatitis, see <a href=\"#3b\" target=\"_self\">M21-1, Part V, Subpart iii, 6.3.b</a>.</span></span></div></td></tr><tr><td style=\"width: 40%; vertical-align: top; padding: 1px;\"><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">non-specific hepatitis and current evidence shows HCV <strong>or</strong> chronic HBV as well as a history of HAV</span></span></div></td><td style=\"width: 59%; vertical-align: top; padding: 1px;\"><div><span style=\"font-family:Arial,Helvetica,sans-serif;\"><span style=\"font-size: 14px\">a medical opinion is necessary to determine whether the current disability is a result of the non-specific hepatitis diagnosed in service.</span></span></div></td></tr></tbody></table><div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.6.3.j<a id=\"3j\" name=\"3j\">.</a> Requesting Exams and/or Opinions for HBV or HCV</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Follow the steps in the table below when requesting an examination and/or opinion for HCV or chronic HBV.</span></span></div><div></div><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-spacing: 0px; border-collapse: revert;\" summary=\"This is a step-action table.  Column 1 is the step number and column 2 provides the actions to take when requesting an examination and/or opinion for HCV or chronic HBV.\" width=\"507\"><thead><tr><th scope=\"col\" style=\"width: 13.5%; padding: 0px;\"><div style=\"text-align: center;\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Step</strong></span></span></div></th><th scope=\"col\" style=\"width: 86.5%; padding: 0px;\"><div style=\"text-align: center;\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Action</strong></span></span></div></th></tr></thead><tbody><tr><td style=\"width: 13%; vertical-align: top; padding: 0px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">1</span></span></div></td><td style=\"width: 86.5%; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Identify and request the examiner review of all relevant evidence in the claims folder.</span></span></div></td></tr><tr><td style=\"width: 13%; vertical-align: top; padding: 0px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">2</span></span></div></td><td style=\"width: 86.5%; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">List any risk factors identified by the Veteran.</span></span></div></td></tr><tr><td style=\"width: 13%; vertical-align: top; padding: 0px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">3</span></span></div></td><td style=\"width: 86.5%; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Identify all risk factors confirmed by the evidence in the claims folder, whether claimed by the Veteran or not.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Important</em></strong>:  In addition to in-service risk factors, ensure that all documented pre- and post-service risk factors are noted in the exam request.</span></span></div></td></tr><tr><td style=\"width: 13%; vertical-align: top; padding: 0px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">4</span></span></div></td><td style=\"width: 86.5%; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Request<em> Hepatitis, Cirrhosis And Other Liver Conditions Disability Benefits Questionnaire</em>.</span></span></div></td></tr><tr><td style=\"width: 13%; vertical-align: top; padding: 0px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">5</span></span></div></td><td style=\"width: 86.5%; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Request a medical opinion about the relationship between the current HBV or HCV infection and confirmed or supported risk factor(s).</span></span></div></td></tr><tr><td style=\"width: 13%; vertical-align: top; padding: 0px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">6</span></span></div></td><td style=\"width: 86.5%; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Notify the examiner that a positive nexus opinion, if warranted, should take only confirmed risk factors as shown by the objective evidence of record into consideration.</span></span></div></td></tr></tbody></table><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>References</em></strong>:  For more information on</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">confirming risk factors, see <a href=\"#3e\" target=\"_self\">M21-1, Part V, Subpart iii, 6.3.e</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">evaluating evidence, see <a articleid=\"554400000014383\" articlename=\"M21-1, Part V, Subpart ii, Chapter 1, Section A - Principles of Reviewing and Weighing Evidence\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014383/M21-1-Part-V-Subpart-ii-Chapter-1-Section-A-Principles-of-Reviewing-and-Weighing-Evidence\">M21-1, Part V, Subpart ii, 1.A</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.6.3.k<a id=\"3k\" name=\"3k\">.</a> Reviewing Hepatitis Exams and Opinions for Sufficiency</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Review the examination or opinion to ensure sufficiency and return insufficient examinations when warranted.  Common reasons for insufficient examinations are</span></span></p><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">lack of proper confirmatory testing to support the diagnosis</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">failure to include complete clinical findings and symptoms in the report</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">failure to address all known risk factors in the opinion</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">opinions linking HCV or chronic HBV to a risk factor that is not confirmed in the evidence of record, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">opinions improperly linking HCV or chronic HBV to a risk factor that is not medically recognized as a source of infection.</span></span></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.6.3.l<a id=\"3l\" name=\"3l\">.</a> Assigning a 0-Percent Evaluation for HCV</span></span></h3></td><td style=\"height: 8px; width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 523px; padding: 0px;\"><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">To assign an evaluation for HCV (<a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR52ba1b312b58845/section-4.114\" target=\"_blank\">38 CFR 4.114, DC 7354</a>) use the criteria in <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR52ba1b312b58845/section-4.114\" target=\"_blank\">38 CFR 4.114, DC 7345</a> (chronic liver disease without cirrhosis).</span></span></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"> </span></span></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">A 0-percent evaluation should only be assigned for HCV when the condition is asymptomatic with a previous history of liver disease. </span></span></div><div></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">Use the table below to determine when it is appropriate to assign a 0-percent evaluation for HCV.</span></span></div><div></div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width: 510px; border-spacing: 1px; border-collapse: revert;\" summary=\"This is an If-Then table.  Column 1 provides the criteria and column 2 provides information to determine when it is appropriate to assign a 0-percent evaluation for HCV.\" width=\"510\"><thead><tr><th scope=\"col\" style=\"width: 258px; padding: 1px;\"><div style=\"text-align: left;\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>If medical evidence shows ...</strong></span></span></div></th><th scope=\"col\" style=\"width: 252px; padding: 1px;\"><div style=\"text-align: left;\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Then a 0-percent disability evaluation is ...</strong></span></span></div></th></tr></thead><tbody><tr><td style=\"width: 258px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">even mild symptoms related to HCV infection</span></span></div></td><td style=\"width: 252px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">not appropriate because the Veteran is symptomatic.</span></span></div></td></tr><tr><td style=\"width: 258px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">there is evidence of liver damage on LFTs, liver biopsy, or other testing</span></span></div></td><td style=\"width: 252px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">not appropriate because this means the infection is not <em>healed</em>.</span></span></div></td></tr><tr><td style=\"width: 258px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">HCV has responded to therapy to the extent that RNA test results are negative, and the Veteran is now asymptomatic with no evidence of liver damage</span></span></div></td><td style=\"width: 252px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">appropriate. However, HCV remains dormant in the system and may flare up again later.</span></span></div></td></tr></tbody></table><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Reference</em></strong>:  For more information on evaluation of HCV, see <a href=\"http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=1&amp;SID=7c54c98c7be24cd2f7b05eabb45f8a87&amp;ty=HTML&amp;h=L&amp;r=SECTION&amp;n=se38.1.4_1114\" target=\"_blank\">38 CFR 4.114, DC 7354</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><p class=\"ng-scope\" style=\"text-align: right\"><span style=\"font-size: 11px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a articleid=\"554400000014520\" articlename=\"M21-1, Part V, Subpart iii, Chapter 5 - Cardiovascular System Conditions\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014520/M21-1-Part-V-Subpart-iii-Chapter-5-Cardiovascular-System-Conditions\">&lt;-- Previous Section</a>  <a articleid=\"554400000180593\" articlename=\"M21-1, Part V, Subpart iii, Chapter 7 - Genitourinary Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180593/M21-1-Part-V-Subpart-iii-Chapter-7-Genitourinary-Disabilities\">Next Section --&gt;</a></span></span></p><p class=\"ng-scope\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#top\" target=\"_self\"><span style=\"font-size: 11px\">To Top</span></a></span></p><p class=\"ng-scope\"></p></div>\n</div>",
  "external_links": [
    "http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=1&SID=7c54c98c7be24cd2f7b05eabb45f8a87&ty=HTML&h=L&r=SECTION&n=se38.1.3_1105",
    "http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=1&SID=7c54c98c7be24cd2f7b05eabb45f8a87&ty=HTML&h=L&r=SECTION&n=se38.1.3_1304",
    "http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=1&SID=7c54c98c7be24cd2f7b05eabb45f8a87&ty=HTML&h=L&r=SECTION&n=se38.1.3_1309",
    "http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=1&SID=7c54c98c7be24cd2f7b05eabb45f8a87&ty=HTML&h=L&r=SECTION&n=se38.1.4_1114",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=11a8c42004846650332ce6e28ab91057&mc=true&node=se38.1.3_1102&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=1e324e06ebb226eb099aa96f320959d2&node=se38.1.3_1159&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=290d6d4d738a59a099fe3225e78f6388&node=se38.1.3_1301&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=642574e012687e22e2367579161048b5&node=se38.1.3_1105&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=678e1a0b35110a17aae704e69f2701f2&mc=true&node=se38.1.4_1114&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=7ba4ca19cef35152b0b6015d80b0df65&node=se38.1.3_1303&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=99923fa4aa6e88e29512e11f1e18ec97&mc=true&node=se38.1.4_1114&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=eb7e5f1a68f287026d33281f48329284&node=se38.1.3_1957&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=f4e5818587afc2385dc0a750e18eb7f4&mc=true&node=se38.1.3_1303&rgn=div8",
    "http://www.vba.va.gov/pubs/forms/VBA-21-526EZ-ARE.pdf",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=2a53e1b0a72d2663bf1e9cacf30abff9&mc=true&node=se38.1.4_1113&rgn=div8https://www.ecfr.gov/cgi-bin/text-idx?SID=2a53e1b0a72d2663bf1e9cacf30abff9&mc=true&node=se38.1.4_1113&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=409c267ffb758e5b31de5f5cb2da025a&mc=true&node=se38.1.4_1114&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=b395daab3d4727abd2b162336385f1c8&mc=true&node=se38.1.3_1951&rgn=div8",
    "https://www.ecfr.gov/compare/2024-03-20/to/2024-03-19/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR52ba1b312b58845/section-4.110",
    "https://www.ecfr.gov/compare/2024-03-20/to/2024-03-19/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR52ba1b312b58845/section-4.111",
    "https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-A/section-4.14",
    "https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-A/section-4.25",
    "https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-A/section-4.7",
    "https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR52ba1b312b58845/section-4.112",
    "https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR52ba1b312b58845/section-4.113",
    "https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR52ba1b312b58845/section-4.114",
    "https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFRef3d6710e800bcd/section-4.114"
  ],
  "scraped_at": "2025-06-16T22:44:58.198937",
  "next_section": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180593/M21-1-Part-V-Subpart-iii-Chapter-7-Genitourinary-Disabilities"
}